Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 640 articles:
HTML format



Single Articles


    July 2022
  1. WANG X, Cai JS, Yang F
    Investigation of the non-small cell lung cancer patients with uncertain resection: A population-based study.
    Lung Cancer. 2022;171:47-55.
    PubMed     Abstract available


  2. SOLBERG S, Nilssen Y, Terje Brustugun O, Magnus Haram P, et al
    Concordance between clinical and pathology TNM-staging in lung cancer.
    Lung Cancer. 2022;171:65-69.
    PubMed     Abstract available


  3. ROBBINS HA, Zahed H, Lebrett MB, Balata H, et al
    Explaining differences in the frequency of lung cancer detection between the National Lung Screening Trial and community-based screening in Manchester, UK.
    Lung Cancer. 2022;171:61-64.
    PubMed     Abstract available


  4. LIU C, Liu C, Liao J, Yin JC, et al
    Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
    Lung Cancer. 2022;171:18-25.
    PubMed     Abstract available


  5. LINDQVIST J, Jekunen A, Sihvo E, Johansson M, et al
    Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients.
    Lung Cancer. 2022;171:9-17.
    PubMed     Abstract available


  6. WOLL P, Gaunt P, Danson S, Steele N, et al
    Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.
    Lung Cancer. 2022;171:26-33.
    PubMed     Abstract available


  7. SUGIMOTO T, Fujimoto D, Sato Y, Tamiya M, et al
    Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
    Lung Cancer. 2022;171:3-8.
    PubMed     Abstract available


  8. ARIFIN AJ, Palma DA
    The changing landscape of pneumonitis in non-small cell lung cancer.
    Lung Cancer. 2022;171:1-2.
    PubMed    


  9. TAKADA K, Takamori S
    Comments on "Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis".
    Lung Cancer. 2022 Jul 5. pii: S0169-5002(22)00541.
    PubMed    


  10. FROST N, Roeper J, Velthaus JL, Raspe M, et al
    Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
    Lung Cancer. 2022;170:165-175.
    PubMed     Abstract available


  11. LUIGI BANNA G, Addeo A, Zygoura P, Tsourti Z, et al
    A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Lung Cancer. 2022;169:77-83.
    PubMed     Abstract available


  12. STOGBAUER F, Lautizi M, Kriegsmann M, Winter H, et al
    Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung - Determination and validation of optimal prognostic cut-offs.
    Lung Cancer. 2022;169:1-12.
    PubMed     Abstract available


    June 2022
  13. WO Y, Li H, Zhang Y, Peng Y, et al
    The impact of station 4L lymph node dissection on short-term and long-term outcomes in non-small cell lung cancer.
    Lung Cancer. 2022;170:141-147.
    PubMed     Abstract available


  14. JIA X, Chu X, Jiang L, Li Y, et al
    Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84].
    Lung Cancer. 2022 Jun 29. pii: S0169-5002(22)00537.
    PubMed    


  15. WEVER BMM, Bach S, Tibbesma M, Ter Braak TJ, et al
    Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: A feasibility study.
    Lung Cancer. 2022;170:156-164.
    PubMed     Abstract available


  16. CORDEIRO DE LIMA VC, Corassa M, Saldanha E, Freitas H, et al
    STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Lung Cancer. 2022;170:114-121.
    PubMed     Abstract available


  17. GORING S, Varol N, Waser N, Popoff E, et al
    Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
    Lung Cancer. 2022;170:122-132.
    PubMed     Abstract available


  18. GAO RW, Day CN, Yu NY, Bush A, et al
    Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.
    Lung Cancer. 2022;170:58-64.
    PubMed     Abstract available


  19. KUANG Y, Pierce CM, Chang HC, Sosinsky AZ, et al
    Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis.
    Lung Cancer. 2022 Jun 11. pii: S0169-5002(22)00469.
    PubMed     Abstract available


  20. MCKEON TP, Anil Vachani, Penning TM, Hwang WT, et al
    Air pollution and lung cancer survival in Pennsylvania.
    Lung Cancer. 2022;170:65-73.
    PubMed     Abstract available


  21. JIA X, Chu X, Jiang L, Li Y, et al
    Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram.
    Lung Cancer. 2022;170:74-84.
    PubMed     Abstract available


  22. TAKAMOCHI K, Hara K, Hayashi T, Kohsaka S, et al
    Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Lung Cancer. 2022;168:50-58.
    PubMed     Abstract available


  23. SWAMI N, Chen TY, Dee EC, Gomez SL, et al
    Adjust, don't avoid: The need for risk-based CT screening in nonsmoking populations.
    Lung Cancer. 2022;168:36-37.
    PubMed    


  24. FANG W, Xu N, Shen Y, Gu Z, et al
    Management of incidentally detected small anterior mediastinal nodules: Which way to go?
    Lung Cancer. 2022;168:30-35.
    PubMed     Abstract available


  25. JEON YJ, Lee J, Shin S, Cho JH, et al
    Prognostic impact of micropapillary and solid histological subtype on patients undergoing curative resection for stage I lung adenocarcinoma according to the extent of pulmonary resection and lymph node assessment.
    Lung Cancer. 2022;168:21-29.
    PubMed     Abstract available


  26. JAIRAM V, Soulos PR, Gross CP, Yu JB, et al
    A reply to "Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC".
    Lung Cancer. 2022;168:84-85.
    PubMed    


  27. LI R, Suo R, Zhang J
    Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC.
    Lung Cancer. 2022;168:83.
    PubMed    


    May 2022
  28. SLEBE M, Pouw JEE, Hashemi SMS, Menke-van der Houven van Oordt CW, et al
    Current state and upcoming opportunities for immunoPET biomarkers in lung cancer.
    Lung Cancer. 2022;169:84-93.
    PubMed     Abstract available


  29. CUPPENS K, Baas P, Geerdens E, Cruys B, et al
    HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Lung Cancer. 2022;170:1-10.
    PubMed     Abstract available


  30. SIGEL K, Yin Kong C, Leiter A, Kale M, et al
    Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities.
    Lung Cancer. 2022;170:34-40.
    PubMed     Abstract available


  31. KIM BR, Sohn JY, Jang EJ, Jo J, et al
    Hospital case-volume and mortality after lung cancer surgery: A population-based retrospective cohort study.
    Lung Cancer. 2022;169:61-66.
    PubMed     Abstract available


  32. RIUDAVETS M, Cascetta P, Planchard D
    Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
    Lung Cancer. 2022;169:102-114.
    PubMed     Abstract available


  33. DONKER HC, Schuuring E, Heitzer E, Groen HJM, et al
    Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer.
    Lung Cancer. 2022;170:52-57.
    PubMed     Abstract available


  34. SOO RA, Huat Tan E, Hayashi H, Seto T, et al
    Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Lung Cancer. 2022;169:67-76.
    PubMed     Abstract available


  35. JOHNSON M, Garassino MC, Mok T, Mitsudomi T, et al
    Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
    Lung Cancer. 2022;170:41-51.
    PubMed     Abstract available


  36. KOLLER M, Musoro JZ, Tomaszewski K, Coens C, et al
    Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72].
    Lung Cancer. 2022 May 20. pii: S0169-5002(22)00436.
    PubMed    


  37. PILOTTO S, Avancini A, Menis J, Sperduti I, et al
    Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey.
    Lung Cancer. 2022;169:94-101.
    PubMed     Abstract available


  38. MOGENET A, Barlesi F, Besse B, Michiels S, et al
    Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.
    Lung Cancer. 2022;169:31-39.
    PubMed     Abstract available


  39. LANG C, Egger F, Alireza Hoda M, Saeed Querner A, et al
    Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis.
    Lung Cancer. 2022;169:40-46.
    PubMed     Abstract available


  40. CHU X, Xu Y, Li Y, Zhou Y, et al
    Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naive non-small cell lung cancer: An under-recognized phenomenon.
    Lung Cancer. 2022;169:22-30.
    PubMed     Abstract available


  41. WILLIAMS RM, Kareff SA, Sackstein P, Roy T, et al
    Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
    Lung Cancer. 2022;169:55-60.
    PubMed     Abstract available


  42. NGO PJ, Wade S, Vaneckova P, Behar Harpaz S, et al
    Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening.
    Lung Cancer. 2022;169:47-54.
    PubMed     Abstract available


  43. GROVER H, King W, Bhattarai N, Moloney E, et al
    Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
    Lung Cancer. 2022;170:20-33.
    PubMed     Abstract available


  44. VELUT Y, Decroix E, Blons H, Alifano M, et al
    SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
    Lung Cancer. 2022;169:13-21.
    PubMed     Abstract available


  45. RYAN DJ, Toomey S, Smyth R, Madden SF, et al
    Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel.
    Lung Cancer. 2022;168:67-73.
    PubMed     Abstract available


  46. LIU X, Li X, Zhang C, Jin J, et al
    EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
    Lung Cancer. 2022;167:78-86.
    PubMed     Abstract available


  47. MEDERER T, Elsner F, Robold T, Grosser C, et al
    EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients.
    Lung Cancer. 2022;167:73-77.
    PubMed     Abstract available


  48. YOSHIDA C, Kadota K, Yamada K, Fujimoto S, et al
    Tumor-associated CD163(+) macrophage as a predictor of tumor spread through air spaces and with CD25(+) lymphocyte as a prognostic factor in resected stage I lung adenocarcinoma.
    Lung Cancer. 2022;167:34-40.
    PubMed     Abstract available


  49. LI W, Ye L, Huang Y, Zhou F, et al
    Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
    Lung Cancer. 2022;167:25-33.
    PubMed     Abstract available


  50. CAMERON JK, Aitken J, Reid A, Mengersen K, et al
    Geographic distribution of malignant mesothelioma incidence and survival in Australia.
    Lung Cancer. 2022;167:17-24.
    PubMed     Abstract available


  51. SCHERPEREEL A, Antonia S, Bautista Y, Grossi F, et al
    First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Lung Cancer. 2022;167:8-16.
    PubMed     Abstract available


  52. GARCIA BNC, van Kempen LC, Kuijpers CCHJ, Schuuring E, et al
    Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
    Lung Cancer. 2022;167:1-7.
    PubMed     Abstract available


  53. MC LEER A, Foll M, Brevet M, Antoine M, et al
    Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
    Lung Cancer. 2022;167:98-106.
    PubMed     Abstract available


    April 2022
  54. TUFMAN A, Redmond K, Giannopoulou A, Gonzalez-McQuire S, et al
    Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey.
    Lung Cancer. 2022;168:59-66.
    PubMed     Abstract available


  55. DICKSON JL, Bhamani A, Quaife SL, Horst C, et al
    The reporting of pulmonary nodule results by letter in a lung cancer screening setting.
    Lung Cancer. 2022;168:46-49.
    PubMed     Abstract available


  56. SCHEFFLER M, Wiesweg M, Michels S, Nogova L, et al
    Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
    Lung Cancer. 2022;168:10-20.
    PubMed     Abstract available


  57. HAYASHI H, Yonesaka K, Nakamura A, Fujimoto D, et al
    Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
    Lung Cancer. 2022;168:38-45.
    PubMed     Abstract available


  58. ZHOU Y, Song L, Xu Q, Zeng L, et al
    Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
    Lung Cancer. 2022;167:58-64.
    PubMed     Abstract available


  59. LEBRETT MB, Crosbie EJ, Yorke J, Hewitt K, et al
    Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme.
    Lung Cancer. 2022;168:1-9.
    PubMed     Abstract available


  60. TORASAWA M, Yoshida T, Yagishita S, Shimoda Y, et al
    Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
    Lung Cancer. 2022;167:49-57.
    PubMed     Abstract available


  61. STEEGHS EMP, Groen HJM, Schuuring E, Aarts MJ, et al
    Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
    Lung Cancer. 2022;167:87-97.
    PubMed     Abstract available


  62. FOURNEL L, Charrier T, Huriet M, Iaffaldano A, et al
    Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients.
    Lung Cancer. 2022;166:221-227.
    PubMed     Abstract available


  63. LI H, Sun Z, Li Y, Qi Q, et al
    Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions.
    Lung Cancer. 2022;166:178-188.
    PubMed     Abstract available


  64. ARCANGELI S, Ramella S
    Postoperative radiotherapy (PORT) in NSCLC: The end of a love? It is never too good to trust what appears.
    Lung Cancer. 2022;166:250-251.
    PubMed    


  65. LI Y, Shi X, Mao B, Wang L, et al
    The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8(+) T cell infiltration in Chinese lung large cell neuroendocrine carcinoma.
    Lung Cancer. 2022;166:161-169.
    PubMed     Abstract available


  66. FENG XL, Wang SZ, Chen HH, Huang YX, et al
    Optimizing the radiomics-machine-learning model based on non-contrast enhanced CT for the simplified risk categorization of thymic epithelial tumors: A large cohort retrospective study.
    Lung Cancer. 2022;166:150-160.
    PubMed     Abstract available


  67. SKRIBEK M, Bozoky B, Tsakonas G
    Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report.
    Lung Cancer. 2022;166:132-134.
    PubMed     Abstract available


  68. SLIMANO F, Le Bozec A, Cransac A, Foucher P, et al
    Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.
    Lung Cancer. 2022;166:114-121.
    PubMed     Abstract available


  69. LEVY B, Barlesi F, Paz-Ares L, Bennouna J, et al
    Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).
    Lung Cancer. 2022;166:107-113.
    PubMed     Abstract available


  70. LIN L, Pan H, Li X, Zhao C, et al
    A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2022;166:98-106.
    PubMed     Abstract available


  71. COPIA SPERANDIO R, Luiza Teixeira Tostes F, Vidal Campregher P, Ribeiro Paes V, et al
    EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
    Lung Cancer. 2022;166:94-97.
    PubMed     Abstract available


  72. NAIDOO J, Vansteenkiste JF, Faivre-Finn C, Ozguroglu M, et al
    Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
    Lung Cancer. 2022;166:84-93.
    PubMed     Abstract available


  73. JOUBERT V, Chalabreysse L, Gamondes D, Tronc F, et al
    Clinical practices for non-neoplastic thymic lesions: Results from a multidisciplinary cohort.
    Lung Cancer. 2022;166:76-83.
    PubMed     Abstract available


  74. VOLTERRANI L, Guerrini S, Zanfrini E, Grassi A, et al
    "HRCT predictors of GGO surgical resection: Histopathological and molecular correlation in the era of lung sparing surgery".
    Lung Cancer. 2022;166:70-75.
    PubMed     Abstract available


  75. VELEZ MA, Tsai HHC, Shackelford DB, Garon EB, et al
    What is the current role of immunotherapy in EGFR mutant advanced NSCLC?
    Lung Cancer. 2022;166:253-254.
    PubMed    


  76. BAUML JM, Li BT, Velcheti V, Govindan R, et al
    Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
    Lung Cancer. 2022;166:270-278.
    PubMed     Abstract available


  77. TAN C, Mandell JD, Dasari K, Cannataro VL, et al
    Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors-on average-to exhibit a lower mutation burden.
    Lung Cancer. 2022;166:265-269.
    PubMed    


    March 2022
  78. KOLLER M, Musoro JZ, Tomaszewski K, Coens C, et al
    Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
    Lung Cancer. 2022;167:65-72.
    PubMed     Abstract available


  79. TAN F, Bi N, Zhang H, Li R, et al
    External validation of the eighth edition of the TNM classification for lung cancer in small cell lung cancer.
    Lung Cancer. 2022;170:98-104.
    PubMed     Abstract available


  80. VAN DER WEIJST L, Aguado-Barrera ME, Azria D, Berkovic P, et al
    Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
    Lung Cancer. 2022;166:228-241.
    PubMed     Abstract available


  81. ROBERT NJ, Espirito JL, Chen L, Nwokeji E, et al
    Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network biomarker testing in metastatic NSCLC with first-line therapy.
    Lung Cancer. 2022;166:197-204.
    PubMed     Abstract available


  82. ZHU YJ, Chang XS, Zhou R, Chen YD, et al
    Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.
    Lung Cancer. 2022;166:189-196.
    PubMed     Abstract available


  83. MCLEAN AEB, Kao SC, Barnes DJ, Wong KKH, et al
    Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132].
    Lung Cancer. 2022 Mar 9. pii: S0169-5002(22)00367.
    PubMed    


  84. JUAREZ-GARCIA A, Sharma R, Hunger M, Kayaniyil S, et al
    Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
    Lung Cancer. 2022;166:205-220.
    PubMed     Abstract available


  85. MINCHOM A, Viteri S, Bazhenova L, Gadgeel SM, et al
    Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Lung Cancer. 2022;168:74-82.
    PubMed     Abstract available


  86. BUTTER R, Hondelink LM, van Elswijk L, Blaauwgeers JLG, et al
    The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
    Lung Cancer. 2022;166:143-149.
    PubMed     Abstract available


  87. EDELMAN MJ, Dvorkin M, Laktionov K, Navarro A, et al
    Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
    Lung Cancer. 2022;166:135-142.
    PubMed     Abstract available


  88. SANTORO A, Su WC, Navarro A, Simonelli M, et al
    Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2022;166:170-177.
    PubMed     Abstract available


  89. CLAERHOUT S, Lehnert S, Vander Borght S, Spans L, et al
    Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
    Lung Cancer. 2022;166:242-249.
    PubMed     Abstract available


    February 2022
  90. NGO PJ, Cressman S, Behar-Harpaz S, Karikios DJ, et al
    Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods.
    Lung Cancer. 2022;166:122-131.
    PubMed     Abstract available


  91. SUN K, Li M, Shang M, Su X, et al
    Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance.
    Lung Cancer. 2022;166:63-69.
    PubMed     Abstract available


  92. KILLINGBERG KT, Halvorsen TO, Flotten O, Brustugun OT, et al
    Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
    Lung Cancer. 2022;166:49-57.
    PubMed     Abstract available


  93. ILIE M, Beaulande M, Long-Mira E, Bontoux C, et al
    Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer.
    Lung Cancer. 2022;166:1-8.
    PubMed     Abstract available


  94. TANG M, Lee CK, Lewis CR, Boyer M, et al
    Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.
    Lung Cancer. 2022;166:40-48.
    PubMed     Abstract available


  95. SCHMID S, Garcia M, Cheng S, Zhan L, et al
    Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2022;166:58-62.
    PubMed     Abstract available


  96. PAZ-ARES L, Gondos A, Saldana D, Thomas M, et al
    Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
    Lung Cancer. 2022;167:41-48.
    PubMed     Abstract available


  97. SOUQUET PJ, Audigier-Valette C, Molinier O, Cortot A, et al
    Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.
    Lung Cancer. 2022;164:84-90.
    PubMed     Abstract available


  98. ARMATO SG, Nowak AK, Francis RJ, Katz SI, et al
    Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group.
    Lung Cancer. 2022;164:76-83.
    PubMed     Abstract available


  99. NAGASAKA M, Balmanoukian AS, Madison R, Zhang SS, et al
    Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
    Lung Cancer. 2022;164:52-55.
    PubMed     Abstract available


  100. BOCH T, Frost N, Sommer L, Overbeck TR, et al
    Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
    Lung Cancer. 2022;164:46-51.
    PubMed     Abstract available


  101. CHEN S, Ye T, Yang S, Zhao Y, et al
    Prognostic implication of tumor spread through air spaces in patients with pathologic N0 lung adenocarcinoma.
    Lung Cancer. 2022;164:33-38.
    PubMed     Abstract available


  102. JAKOBSEN AK, Yuusufi S, Madsen LB, Meldgaard P, et al
    TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data.
    Lung Cancer. 2022;164:23-32.
    PubMed     Abstract available


  103. ZHANG S, Lin D, Yu Y, Cao Q, et al
    Which will carry more weight when CTR > 0.5, solid component size, CTR, tumor size or SUVmax?
    Lung Cancer. 2022;164:14-22.
    PubMed     Abstract available


  104. RODRIGUEZ-ABREU D, Cobo M, Garcia-Roman S, Viteri-Ramirez S, et al
    The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
    Lung Cancer. 2022;164:8-13.
    PubMed     Abstract available


  105. DEBIEUVRE D, Dayen C, Dixmier A, Pau D, et al
    FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
    Lung Cancer. 2022;164:1-7.
    PubMed     Abstract available


    January 2022
  106. WU J, Hou L, E H, Zhao Y, et al
    Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
    Lung Cancer. 2022;165:115-123.
    PubMed     Abstract available


  107. ZHANG J, IJzerman MJ, Oberoi J, Karnchanachari N, et al
    Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes.
    Lung Cancer. 2022;166:27-39.
    PubMed     Abstract available


  108. HUANG LT, Zhang SL, Han CB, Ma JT, et al
    Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Lung Cancer. 2022;166:9-16.
    PubMed     Abstract available


  109. ZHAO JJ, Chan HP, Soon YY, Huang Y, et al
    A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer.
    Lung Cancer. 2022;166:17-26.
    PubMed     Abstract available


  110. CUI W, Milner-Watts C, McVeigh TP, Minchom A, et al
    A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.
    Lung Cancer. 2022;165:34-42.
    PubMed     Abstract available


  111. MCLEAN AEB, Kao SC, Barnes DJ, Wong KKH, et al
    The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment.
    Lung Cancer. 2022;165:124-132.
    PubMed     Abstract available


  112. LI M, Hou X, Chen J, Zhang B, et al
    ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061).
    Lung Cancer. 2022;165:54-62.
    PubMed     Abstract available


  113. CHEN Y, Yang H, Cheng Z, Chen L, et al
    A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer.
    Lung Cancer. 2022;165:18-27.
    PubMed     Abstract available


  114. DEBOEVER N, McGrail DJ, Lee Y, Tran HT, et al
    Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.
    Lung Cancer. 2022;164:69-75.
    PubMed     Abstract available


  115. OBIOLS C, Call S, Rami-Porta R, Jaen A, et al
    Radicality of lymphadenectomy in lung cancer resections by thoracotomy and video-assisted thoracoscopic approach: A prospective, multicentre and propensity-score adjusted study.
    Lung Cancer. 2022;165:63-70.
    PubMed     Abstract available


  116. LANCASTER HL, Zheng S, Aleshina OO, Yu D, et al
    Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification.
    Lung Cancer. 2022;165:133-140.
    PubMed     Abstract available


  117. FUKUI M, Suzuki K, Ando K, Matsunaga T, et al
    Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia.
    Lung Cancer. 2022;165:108-114.
    PubMed     Abstract available


  118. YANG S, Shih YT, Huo J, Mehta HJ, et al
    Procedural complications associated with invasive diagnostic procedures after lung cancer screening with low-dose computed tomography.
    Lung Cancer. 2022;165:141-144.
    PubMed     Abstract available


  119. LIAO G, Huang L, Wu S, Zhang P, et al
    Preoperative CT-based peritumoral and tumoral radiomic features prediction for tumor spread through air spaces in clinical stage I lung adenocarcinoma.
    Lung Cancer. 2022;163:87-95.
    PubMed     Abstract available


  120. KLEBE S, Galateau Salle F, Bruno R, Brcic L, et al
    The highlights of the 15th international conference of the international mesothelioma interest group - Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?
    Lung Cancer. 2022;163:1-6.
    PubMed     Abstract available


    December 2021
  121. HE LN, Chen T, Fu S, Chen C, et al
    Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
    Lung Cancer. 2021;165:10-17.
    PubMed     Abstract available


  122. EVERS J, Hendriks LEL, De Jaeger K, Wijsman R, et al
    Corrigendum to "Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands" [Lung Cancer 162C (2021) 61-70].
    Lung Cancer. 2021 Dec 29. pii: S0169-5002(21)00640.
    PubMed    


  123. COLEMAN N, Harbery A, Heuss S, Vivanco I, et al
    Targeting un-MET needs in advanced non-small cell lung cancer.
    Lung Cancer. 2021;164:56-68.
    PubMed     Abstract available


  124. CHANG J, Wu YL, Lu S, Wang J, et al
    Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
    Lung Cancer. 2021;165:71-81.
    PubMed     Abstract available


  125. KENMOTSU H, Mori K, Mizuno R, Mamesaya N, et al
    Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naive patients with extensive-stage small-cell lung cancer.
    Lung Cancer. 2021;164:39-45.
    PubMed     Abstract available


  126. DESAI A, Abdayem P, Adjei AA, Planchard D, et al
    Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Lung Cancer. 2021;163:96-106.
    PubMed     Abstract available


  127. MURAKAMI H, Horinouchi H, Harada H, Sobue T, et al
    Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study.
    Lung Cancer. 2021;165:152-163.
    PubMed     Abstract available


  128. FRIESE-HAMIM M, Clark A, Perrin D, Crowley L, et al
    Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
    Lung Cancer. 2021;163:77-86.
    PubMed     Abstract available


  129. LIN T, Pham J, Paul E, Conron M, et al
    Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study.
    Lung Cancer. 2021;163:69-76.
    PubMed     Abstract available


  130. MAINGUENE J, Basse C, Girard P, Beaucaire-Danel S, et al
    Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.
    Lung Cancer. 2021;163:51-58.
    PubMed     Abstract available


  131. RIUDAVETS M, Naigeon M, Texier M, Dorta M, et al
    Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
    Lung Cancer. 2021 Dec 3. pii: S0169-5002(21)00624.
    PubMed     Abstract available


  132. MARKS S, Naidoo J
    Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Lung Cancer. 2021;163:59-68.
    PubMed     Abstract available


  133. HA DM, Prochazka AV, Bekelman DB, Stevens-Lapsley JE, et al
    Modifiable factors associated with health-related quality of life among lung cancer survivors following curative intent therapy.
    Lung Cancer. 2021;163:42-50.
    PubMed     Abstract available


  134. BRYANT AK, Sankar K, Strohbehn GW, Zhao L, et al
    Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2021;163:35-41.
    PubMed     Abstract available


  135. GUO LW, Lyu ZY, Meng QC, Zheng LY, et al
    A risk prediction model for selecting high-risk population for computed tomography lung cancer screening in China.
    Lung Cancer. 2021;163:27-34.
    PubMed     Abstract available


  136. PLUMMER R, Dean E, Arkenau HT, Redfern C, et al
    A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2021;163:19-26.
    PubMed     Abstract available


  137. BAAS P, Daumont MJ, Lacoin L, Penrod JR, et al
    Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Lung Cancer. 2021;162:185-193.
    PubMed     Abstract available


  138. KWOK WC, Chiang KY, Ho JCM, Lam DCL, et al
    Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung.
    Lung Cancer. 2021;162:169-174.
    PubMed     Abstract available


  139. NOWAK AK, Chin WL, Keam S, Cook A, et al
    Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
    Lung Cancer. 2021;162:162-168.
    PubMed     Abstract available


  140. BAZHENOVA L, Minchom A, Viteri S, Bauml JM, et al
    Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.
    Lung Cancer. 2021;162:154-161.
    PubMed     Abstract available


  141. SUZUKI M, Matsumoto Y, Imabayashi T, Teishikata T, et al
    Cryobiopsy as a reliable technique for the preoperative identification of micropapillary/solid components in early-stage lung adenocarcinoma.
    Lung Cancer. 2021;162:147-153.
    PubMed     Abstract available


  142. SAITO T, Ono R, Tanaka Y, Tatebayashi D, et al
    The effect of home-based preoperative pulmonary rehabilitation before lung resection: A retrospective cohort study.
    Lung Cancer. 2021;162:135-139.
    PubMed     Abstract available


  143. FJAELLEGAARD K, Koefod Petersen J, Reuter S, Malene Fischer B, et al
    Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis.
    Lung Cancer. 2021;162:106-118.
    PubMed     Abstract available


  144. WU Y, Yang M, Chen R, Ou SI, et al
    Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations.
    Lung Cancer. 2021;162:207-209.
    PubMed    


  145. LIANG Q, Xu H, Liu Y, Zhang W, et al
    Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Lung Cancer. 2021;162:86-89.
    PubMed     Abstract available


  146. FILIPPI AR, Garassino M, Shirvani SM, Feldman J, et al
    Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy - A path forward?
    Lung Cancer. 2021;162:203-206.
    PubMed    


  147. HAMADA A, Suda K, Koga T, Fujino T, et al
    In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
    Lung Cancer. 2021;162:79-85.
    PubMed     Abstract available


  148. SCHAKENRAAD A, Hashemi S, Twisk J, Houda I, et al
    The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors.
    Lung Cancer. 2021;162:36-41.
    PubMed     Abstract available


  149. CHIEN YN, Lin YC, Chang CL, Lin WC, et al
    Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment.
    Lung Cancer. 2021;162:29-35.
    PubMed     Abstract available


  150. GUTIERREZ M, Guo R, Giaccone G, Liu SV, et al
    Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers.
    Lung Cancer. 2021;162:23-28.
    PubMed     Abstract available


  151. POPAT S, Jung HA, Lee SY, Hochmair MJ, et al
    Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Lung Cancer. 2021;162:9-15.
    PubMed     Abstract available


    November 2021
  152. KOK PS, Lee K, Lord S, John T, et al
    Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer.
    Lung Cancer. 2021;163:14-18.
    PubMed     Abstract available


  153. TAN DS, Thomas M, Kim DW, Szpakowski S, et al
    Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Lung Cancer. 2021;163:7-13.
    PubMed     Abstract available


  154. MATSUMOTO K, Shiroyama T, Kuge T, Miyake K, et al
    Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021;162:175-184.
    PubMed     Abstract available


  155. LIU Q, Qiao M, Lohinai Z, Mao S, et al
    CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer.
    Lung Cancer. 2021 Nov 11. pii: S0169-5002(21)00596.
    PubMed     Abstract available


  156. ISAKA T, Ito H, Nakayama H, Yokose T, et al
    Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
    Lung Cancer. 2021;162:128-134.
    PubMed     Abstract available


  157. GIRARD N, Perol M, Simon G, Audigier Valette C, et al
    Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.
    Lung Cancer. 2021;162:119-127.
    PubMed     Abstract available


  158. CROCKETT C, Belderbos J, Levy A, McDonald F, et al
    Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?
    Lung Cancer. 2021;162:96-105.
    PubMed     Abstract available


  159. ZHU Y, Cai Q, Wang Y, You N, et al
    Pre-surgical assessment of mediastinal lymph node metastases in patients having >/= 30 mm non-small-cell lung cancers.
    Lung Cancer. 2021;161:189-196.
    PubMed     Abstract available


  160. TAKAMOCHI K, Hara K, Hayashi T, Kohsaka S, et al
    Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Lung Cancer. 2021;161:163-170.
    PubMed     Abstract available


  161. CIRNE F, Zhou S, Kappel C, El-Kadi A, et al
    ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.
    Lung Cancer. 2021;161:9-17.
    PubMed     Abstract available


  162. ZHOU N, Velez MA, Bachrach B, Gukasyan J, et al
    Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
    Lung Cancer. 2021;161:34-41.
    PubMed     Abstract available


    October 2021
  163. EVERS J, Hendriks LEL, De Jaeger K, Wijsman R, et al
    Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;162:61-70.
    PubMed     Abstract available


  164. GAO L, Shen L, Wang K, Lu S, et al
    Propensity score matched analysis for the role of surgery in stage small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital.
    Lung Cancer. 2021;162:54-60.
    PubMed     Abstract available


  165. DEMEDTS I, Himpe U, Bossuyt J, Anthoons G, et al
    Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients.
    Lung Cancer. 2021;162:90-95.
    PubMed     Abstract available


  166. POMPILI C, Rogers Z, Absolom K, Holch P, et al
    Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study.
    Lung Cancer. 2021;162:71-78.
    PubMed     Abstract available


  167. BUMA AIG, Muller M, de Vries R, Sterk PJ, et al
    Corrigendum to "eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer" [Lung Cancer 160 (2021) 36-43].
    Lung Cancer. 2021 Oct 22. pii: S0169-5002(21)00576.
    PubMed    


  168. YASUDA H, Ichihara E, Sakakibara-Konishi J, Zenke Y, et al
    A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
    Lung Cancer. 2021;162:140-146.
    PubMed     Abstract available


  169. MONDACA S, Lebow ES, Namakydoust A, Razavi P, et al
    Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73].
    Lung Cancer. 2021 Oct 5. pii: S0169-5002(21)00552.
    PubMed    


  170. ZHOU N, Jiang M, Li T, Zhu J, et al
    Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.
    Lung Cancer. 2021;160:111-117.
    PubMed     Abstract available


  171. TOTA V, Dagonnier M, Wery D, Binet L, et al
    Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review.
    Lung Cancer. 2021;160:59-65.
    PubMed     Abstract available


  172. SHAH P, Sands J, Normanno N
    The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.
    Lung Cancer. 2021;160:118-126.
    PubMed     Abstract available


  173. LIU D, Xu X, Wen J, Zhang C, et al
    Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Lung Cancer. 2021;160:32-35.
    PubMed     Abstract available


  174. AOKAGE K, Miyoshi T, Wakabayashi M, Ikeno T, et al
    Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
    Lung Cancer. 2021;160:8-16.
    PubMed     Abstract available


    September 2021
  175. MODY GN, Stover AM, Wang M, King-Kallimanis BL, et al
    Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).
    Lung Cancer. 2021;162:1-8.
    PubMed     Abstract available


  176. LI M, Zhang C, Deng S, Li L, et al
    Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer.
    Lung Cancer. 2021;162:16-22.
    PubMed     Abstract available


  177. JOOSTEN PJM, de Langen AJ, van der Noort V, Monkhorst K, et al
    The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
    Lung Cancer. 2021;161:141-151.
    PubMed     Abstract available


  178. TU Z, Li C, Tian T, Chen Q, et al
    A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion.
    Lung Cancer. 2021;161:114-121.
    PubMed     Abstract available


  179. KRAMER T, Annema JT
    Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer.
    Lung Cancer. 2021;161:152-162.
    PubMed     Abstract available


  180. MAAT APWM, Cornelissen R, Bogers AJJC, Mahtab EAF, et al
    Erratum to "Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions''' [Lung Cancer 159 (2021) 127].
    Lung Cancer. 2021 Sep 20. pii: S0169-5002(21)00539.
    PubMed    


  181. BALATA H, Ruparel M, O'Dowd E, Ledson M, et al
    Analysis of the baseline performance of five UK lung cancer screening programmes.
    Lung Cancer. 2021;161:136-140.
    PubMed     Abstract available


  182. BARANY N, Rozsas A, Megyesfalvi Z, Grusch M, et al
    Clinical relevance of circulating activin A and follistatin in small cell lung cancer.
    Lung Cancer. 2021;161:128-135.
    PubMed     Abstract available


  183. AULIAC JB, Monnet I, Bizieux A, Greillier L, et al
    Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
    Lung Cancer. 2021;161:122-127.
    PubMed     Abstract available


  184. JAIRAM V, Pasha S, Soulos PR, Gross CP, et al
    Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques.
    Lung Cancer. 2021;161:171-179.
    PubMed     Abstract available


  185. CLARKE JM, Patel JD, Robert F, Kio EA, et al
    Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
    Lung Cancer. 2021;161:180-188.
    PubMed     Abstract available


  186. HARADA G, Santini FC, Wilhelm C, Drilon A, et al
    NTRK fusions in lung cancer: From biology to therapy.
    Lung Cancer. 2021;161:108-113.
    PubMed     Abstract available


  187. AGGARWAL C, Bubendorf L, Cooper WA, Illei P, et al
    Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
    Lung Cancer. 2021;162:42-53.
    PubMed     Abstract available


  188. BOUDY AS, Grausz N, Selleret L, Gligorov J, et al
    Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma.
    Lung Cancer. 2021;161:68-75.
    PubMed     Abstract available


  189. WINKELMAN JA, van der Woude L, Heineman DJ, Bahce I, et al
    A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S).
    Lung Cancer. 2021;161:42-48.
    PubMed     Abstract available


  190. SAITO G, Oya Y, Taniguchi Y, Kawachi H, et al
    Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Lung Cancer. 2021;161:86-93.
    PubMed     Abstract available


  191. CASTELLANOS SH, Pagano A, Plodkowski AJ, Girshman J, et al
    Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
    Lung Cancer. 2021;161:60-67.
    PubMed     Abstract available


  192. ANDREANO A, Bergamaschi W, Russo AG
    Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort.
    Lung Cancer. 2021;159:145-152.
    PubMed     Abstract available


  193. GAO J, Zhang L, Li Z, Wang F, et al
    UniPortal thoracoscopic pneumonectomy does not compromise perioperative and long-term survival in patients with NSCLC: A retrospective, multicenter, and propensity score matching study.
    Lung Cancer. 2021;159:135-144.
    PubMed     Abstract available



  194. Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions'.
    Lung Cancer. 2021;159:127.
    PubMed    


  195. BITTONI M, Yang JC, Shih JY, Peled N, et al
    Real-world insights into patients with advanced NSCLC and MET alterations.
    Lung Cancer. 2021;159:96-106.
    PubMed     Abstract available


  196. KIM RY, Li Y, Marmarelis ME, Vachani A, et al
    Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Lung Cancer. 2021;159:107-110.
    PubMed     Abstract available


  197. OIWA H, Aokage K, Suzuki A, Sato K, et al
    Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis.
    Lung Cancer. 2021;159:74-83.
    PubMed     Abstract available


  198. MONDACA S, Lebow ES, Namakydoust A, Razavi P, et al
    Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
    Lung Cancer. 2021;159:66-73.
    PubMed     Abstract available


  199. SEBAN RD, Assie JB, Giroux-Leprieur E, Massiani MA, et al
    Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Lung Cancer. 2021;159:45-55.
    PubMed     Abstract available


  200. MAUCLET C, Collard P, Ghaye B, Hoton D, et al
    Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF(V600) mutation as an acquired resistance mechanism.
    Lung Cancer. 2021;159:42-44.
    PubMed     Abstract available


  201. LAM TC, Tsang KC, Choi HC, Lee VH, et al
    Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
    Lung Cancer. 2021;159:18-26.
    PubMed     Abstract available


  202. DEMPKE WCM, Reck M
    KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
    Lung Cancer. 2021;159:10-17.
    PubMed     Abstract available


  203. ZHANG J, Huang J, Li Q, Lin H, et al
    DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
    Lung Cancer. 2021;159:171-174.
    PubMed    


  204. CHANG HC, Ko PH, Chang YS, Chou PC, et al
    Acute generalized exanthematous pustulosis induced by atezolizumab in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;159:175-176.
    PubMed    


  205. ROSSI UG, Rossi GA
    Pulmonary anatomy, pathology and treatment: What will be the artificial intelligence and deep-learning role on them?
    Lung Cancer. 2021;159:181-182.
    PubMed    


    August 2021
  206. MORIMOTO K, Yamada T, Yokoi T, Kijima T, et al
    Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2021;161:26-33.
    PubMed     Abstract available


  207. NORO R, Igawa S, Bessho A, Hirose T, et al
    A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
    Lung Cancer. 2021;161:49-54.
    PubMed     Abstract available


  208. NAGASAKA M, Asad MFB, Al Hallak MN, Uddin MH, et al
    Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).
    Lung Cancer. 2021;160:92-98.
    PubMed     Abstract available


  209. MOORE DA, Benafif S, Poskitt B, Argue S, et al
    Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.
    Lung Cancer. 2021;161:55-59.
    PubMed     Abstract available


  210. KULASINGHE A, O'Leary C, Monkman J, Bharti V, et al
    The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2021;160:73-77.
    PubMed     Abstract available


  211. VOGGEL S, Abele M, Seitz C, Agaimy A, et al
    Primary lung carcinoma in children and adolescents - Clinical characteristics and outcome of 12 cases from the German registry for rare paediatric tumours (STEP).
    Lung Cancer. 2021;160:66-72.
    PubMed     Abstract available


  212. CHEUNG CC, Smith AC, Albadine R, Bigras G, et al
    Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
    Lung Cancer. 2021;160:127-135.
    PubMed     Abstract available


  213. VAUCHIER C, Pluvy J, Theou-Anton N, Soussi G, et al
    Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.
    Lung Cancer. 2021;160:28-31.
    PubMed     Abstract available


  214. STEENDAM CMJ, Peric R, van Walree NC, Youssef M, et al
    Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.
    Lung Cancer. 2021;160:44-49.
    PubMed     Abstract available


  215. VERMA V
    Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?
    Lung Cancer. 2021 Aug 3. pii: S0169-5002(21)00485.
    PubMed    


  216. BUMA AIG, Muller M, de Vries R, Sterk PJ, et al
    eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.
    Lung Cancer. 2021;160:36-43.
    PubMed     Abstract available


  217. ZHANG SS, Nagasaka M, Zhu VW, Ou SI, et al
    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Lung Cancer. 2021;158:126-136.
    PubMed     Abstract available


  218. NAKASONE S, Suzuki A, Okazaki H, Onodera K, et al
    Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.
    Lung Cancer. 2021;158:115-125.
    PubMed     Abstract available


  219. TOMASIK B, Bienkowski M, Braun M, Popat S, et al
    Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score >/=2 - Systematic review and meta-analysis.
    Lung Cancer. 2021;158:97-106.
    PubMed     Abstract available


  220. YOSHIDA C, Kadota K, Ikeda T, Ibuki E, et al
    Tumor-associated macrophage infiltration is associated with a higher rate of tumor spread through air spaces in resected lung adenocarcinomas.
    Lung Cancer. 2021;158:91-96.
    PubMed     Abstract available


  221. HE Z, Zhu X, Zeng Q, Yu Z, et al
    A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;158:164-165.
    PubMed    


  222. FEKKAR A, Emprou C, Lefebvre C, Ferretti G, et al
    Thoracic NUT carcinoma: Common pathological features despite diversity of clinical presentations.
    Lung Cancer. 2021;158:55-59.
    PubMed     Abstract available


  223. LU A, Shi Y, Liu Y, Lin J, et al
    Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma.
    Lung Cancer. 2021;158:29-39.
    PubMed     Abstract available


  224. LIU SV
    NRG1 fusions: Biology to therapy.
    Lung Cancer. 2021;158:25-28.
    PubMed     Abstract available


  225. KUIJVENHOVEN JC, Livi V, Szlubowski A, Ninaber M, et al
    Endobronchial ultrasound for T4 staging in patients with resectable NSCLC.
    Lung Cancer. 2021;158:18-24.
    PubMed     Abstract available


  226. CYTRYN S, Ferreira V, Boland P, Chachoua A, et al
    Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
    Lung Cancer. 2021;158:15-17.
    PubMed     Abstract available


  227. INGLEY KM, Hughes D, Hubank M, Lindsay D, et al
    Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
    Lung Cancer. 2021;158:151-155.
    PubMed     Abstract available


  228. CHEN X, Xu BO, Fu F, Cai K, et al
    A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK+ in NSCLC.
    Lung Cancer. 2021;158:162-163.
    PubMed    


    July 2021
  229. YOH K, Matsumoto S, Furuya N, Nishino K, et al
    Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2021;159:128-134.
    PubMed     Abstract available


  230. KOOMEN BM, Voorham QJM, Epskamp-Kuijpers CCHJ, van Dooijeweert C, et al
    Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients.
    Lung Cancer. 2021;159:117-126.
    PubMed     Abstract available


  231. KOZONO DE, Stinchcombe TE, Salama JK, Bogart J, et al
    Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2021;159:56-65.
    PubMed     Abstract available


  232. ZHAO M, Wu J, Deng J, Wang T, et al
    Proposal for Rib invasion as an independent T descriptor for non-small cell lung cancer: A propensity-score matching analysis.
    Lung Cancer. 2021;159:27-33.
    PubMed     Abstract available


  233. DIAZ M, Garcia M, Vidal C, Santiago A, et al
    Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis.
    Lung Cancer. 2021;159:153-161.
    PubMed     Abstract available


  234. SAFAVI AH, Mak DY, Boldt RG, Chen H, et al
    Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021 Jul 21. pii: S0169-5002(21)00472.
    PubMed     Abstract available


  235. WANG X, Guo Y, Liu L, Wei J, et al
    YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes.
    Lung Cancer. 2021 Jul 21. pii: S0169-5002(21)00456.
    PubMed     Abstract available


  236. RAD HS, Rad HS, Shiravand Y, Radfar P, et al
    The Pandora's box of novel technologies that may revolutionize lung cancer.
    Lung Cancer. 2021;159:34-41.
    PubMed     Abstract available


  237. VAN BREESCHOTEN J, Ismail R, Smit H, Schuurbiers O, et al
    An invisible group of COVID-19 victims; impact on Dutch lung cancer care.
    Lung Cancer. 2021 Jul 19. pii: S0169-5002(21)00476.
    PubMed    


  238. CHO BC, Yoh K, Perets R, Nagrial A, et al
    Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Lung Cancer. 2021;159:162-170.
    PubMed     Abstract available


  239. SHEN Y, Zhang Y, Guo Y, Li W, et al
    Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis.
    Lung Cancer. 2021;159:111-116.
    PubMed     Abstract available


  240. KOCHER F, Tymoszuk P, Amann A, Sprung S, et al
    Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.
    Lung Cancer. 2021;159:84-95.
    PubMed     Abstract available


  241. USUZAKI T, Takahashi K, Umemiya K, Ishikuro M, et al
    Augmentation method for convolutional neural network that improves prediction performance in the task of classifying primary lung cancer and lung metastasis using CT images.
    Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00468.
    PubMed    


  242. LINDSAY CR, Garassino MC, Nadal E, Ohrling K, et al
    On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00474.
    PubMed     Abstract available


  243. BHALLA S, Bakouny Z, Schmidt AL, Labaki C, et al
    Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.
    Lung Cancer. 2021;160:78-83.
    PubMed     Abstract available


  244. FUNG AS, Graham DM, Chen EX, Stockley TL, et al
    A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
    Lung Cancer. 2021;157:21-29.
    PubMed     Abstract available


  245. POPAT S, Brustugun OT, Cadranel J, Felip E, et al
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer. 2021;157:9-16.
    PubMed     Abstract available


  246. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
    Lung Cancer. 2021;157:167.
    PubMed    


  247. CLERMIDY H, Maury JM, Collaud S, Drevet G, et al
    Lymph Node Dissection in Thymoma: Is it worth it?
    Lung Cancer. 2021;157:156-162.
    PubMed     Abstract available


  248. XIE XJ, Liu SY, Chen JY, Zhao Y, et al
    Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
    Lung Cancer. 2021;157:30-39.
    PubMed     Abstract available


  249. TALCOTT WJ, Miccio JA, Park HS, White AA, et al
    Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
    Lung Cancer. 2021;157:17-20.
    PubMed     Abstract available


  250. ZHU VW, Zhao JJ, Gao Y, Syn NL, et al
    Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Lung Cancer. 2021;157:147-155.
    PubMed     Abstract available


  251. LESIRE B, Durieux V, Grigoriu B, Girard N, et al
    Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.
    Lung Cancer. 2021;157:131-146.
    PubMed     Abstract available


  252. SUGIMOTO A, Umemura S, Miyoshi T, Nakai T, et al
    High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Lung Cancer. 2021;157:1-8.
    PubMed     Abstract available


  253. YANG Y, Ran J, Wang Y, Zhou Z, et al
    Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases.
    Lung Cancer. 2021;157:116-123.
    PubMed     Abstract available


  254. PASSIGLIA F, Leone G, Olmetto E, Delcuratolo MD, et al
    Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.
    Lung Cancer. 2021;157:85-91.
    PubMed     Abstract available


  255. BASSE C, Daniel C, Livartowski A, Beaucaire-Danel S, et al
    Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
    Lung Cancer. 2021;157:79-84.
    PubMed     Abstract available


  256. CHINTALA NK, Restle D, Quach H, Saini J, et al
    CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
    Lung Cancer. 2021;157:48-59.
    PubMed     Abstract available


  257. CERESOLI GL, Ghirardelli P, Franceschini D, Scorsetti M, et al
    A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy".
    Lung Cancer. 2021;157:165-166.
    PubMed    


  258. BARSKY AR, Yegya-Raman N, Katz SI, Simone CB 2nd, et al
    Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy.
    Lung Cancer. 2021;157:163-164.
    PubMed    


    June 2021
  259. SU PL, Tsai JS, Yang SC, Wu YL, et al
    Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.
    Lung Cancer. 2021;158:137-145.
    PubMed     Abstract available


  260. WANG Z, Zhao J, Ma Z, Cui J, et al
    Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268].
    Lung Cancer. 2021 Jun 11. pii: S0169-5002(21)00426.
    PubMed    


  261. BORG M, Wen SWC, Nederby L, Hansen TF, et al
    Performance of the EarlyCDT(R) Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Lung Cancer. 2021;158:85-90.
    PubMed     Abstract available


  262. QI M, Bian D, Zhang J, Zhu X, et al
    The modification of T description according to visceral pleural invasion and tumor size from 3.1cm to 4.0cm in non-small cell lung cancer: A retrospective analysis based on the SEER database.
    Lung Cancer. 2021;158:47-54.
    PubMed     Abstract available


  263. MELOSKY B, Wheatley-Price P, Juergens RA, Sacher A, et al
    The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Lung Cancer. 2021 Jun 5. pii: S0169-5002(21)00429.
    PubMed     Abstract available


  264. JOSHI K, Muhith A, Obeid M, Milner-Watts C, et al
    Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
    Lung Cancer. 2021;156:147-150.
    PubMed     Abstract available


  265. GACHECHILADZE M, Uberall I, Skanderova D, Matchavariani J, et al
    LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2021;156:129-135.
    PubMed     Abstract available


  266. LAROSE F, Quigley N, Lacasse Y, Martel S, et al
    Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
    Lung Cancer. 2021;156:151-156.
    PubMed     Abstract available


  267. PRIETO M, Chassagnon G, Lupo A, Charpentier MC, et al
    Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.
    Lung Cancer. 2021;156:117-121.
    PubMed     Abstract available


  268. SOLDATH P, Binderup T, Kjaer A, Federspiel B, et al
    Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients.
    Lung Cancer. 2021;156:109-116.
    PubMed     Abstract available


  269. LAU SCM, Poletes C, Le LW, Mackay KM, et al
    Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lung Cancer. 2021;156:76-81.
    PubMed     Abstract available


  270. NAKASUKA T, Ohashi K, Watanabe H, Kubo T, et al
    A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
    Lung Cancer. 2021;156:1-4.
    PubMed     Abstract available


    May 2021
  271. KIM HW, Kim JS, Lee SH
    Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Lung Cancer. 2021;158:107-114.
    PubMed     Abstract available


  272. GUO T, Zhu L, Li W, Lin R, et al
    Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
    Lung Cancer. 2021;161:94-97.
    PubMed     Abstract available


  273. SATO T, Shimada Y, Mimae T, Tsutani Y, et al
    The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.
    Lung Cancer. 2021;158:9-14.
    PubMed     Abstract available


  274. HE LN, Fu S, Zhang X, Hu Q, et al
    Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    Lung Cancer. 2021;158:1-8.
    PubMed     Abstract available


  275. LAVOLE A, Mazieres J, Schneider S, Brosseau S, et al
    Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
    Lung Cancer. 2021;158:146-150.
    PubMed     Abstract available


  276. DI STASIO GD, Travascio L, Colandrea M, Spaggiari L, et al
    Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
    Lung Cancer. 2021;158:40-46.
    PubMed     Abstract available


  277. GOKER E, Altwairgi A, Al-Omair A, Tfayli A, et al
    Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations.
    Lung Cancer. 2021;158:60-73.
    PubMed     Abstract available


  278. LIU R, Ota K, Iwama E, Yoneshima Y, et al
    Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
    Lung Cancer. 2021 May 25. pii: S0169-5002(21)00403.
    PubMed     Abstract available


  279. SPIRA AI, Tu H, Aggarwal S, Hsu H, et al
    A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Lung Cancer. 2021;159:1-9.
    PubMed     Abstract available


  280. OSTI MF, Agolli L, Valeriani M, Reverberi C, et al
    Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].
    Lung Cancer. 2021 May 21. pii: S0169-5002(21)00187.
    PubMed    


  281. DUVERGE L, Bondiau PY, Claude L, Supiot S, et al
    Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
    Lung Cancer. 2021 May 15. pii: S0169-5002(21)00195.
    PubMed     Abstract available


  282. PROVENCIO M, Mazarico Gallego JM, Calles A, Antonanzas M, et al
    Lung cancer patients with COVID-19 in Spain: GRAVID study.
    Lung Cancer. 2021 May 14. pii: S0169-5002(21)00193.
    PubMed     Abstract available


  283. WISLEZ M, Domblides C, Greillier L, Mazieres J, et al
    Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00192.
    PubMed     Abstract available


  284. PILLERON S, Maringe C, Charvat H, Atkinson J, et al
    Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00194.
    PubMed     Abstract available


  285. ROGASCH JMM, Frost N, Bluemel S, Michaels L, et al
    FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
    Lung Cancer. 2021 May 7. pii: S0169-5002(21)00171.
    PubMed     Abstract available


  286. LEI H, Yang Y, Zhou W, Zhang M, et al
    Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
    Lung Cancer. 2021 May 5. pii: S0169-5002(21)00170.
    PubMed     Abstract available


  287. WANG LL, Yu H, Wang HY, Liu T, et al
    Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2021 May 3. pii: S0169-5002(21)00168.
    PubMed    


  288. OSAROGIAGBON RU
    The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events.
    Lung Cancer. 2021;155:191-192.
    PubMed    


  289. HALMOS B, Burke T, Kalyvas C, Vandormael K, et al
    Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
    Lung Cancer. 2021;155:175-182.
    PubMed     Abstract available


  290. SUMI T, Nakata H, Chiba H
    Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment.
    Lung Cancer. 2021;155:196-198.
    PubMed    


  291. LUO Y, Wei J, Zhang J, Zeng L, et al
    Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
    Lung Cancer. 2021;155:170-174.
    PubMed     Abstract available


  292. NOORDHOF AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al
    Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Lung Cancer. 2021;155:163-169.
    PubMed     Abstract available


  293. VAN DE STADT EA, Yaqub M, Lammertsma AA, Poot AJ, et al
    Identifying advanced stage NSCLC patients who benefit from afatinib therapy using (18)F-afatinib PET/CT imaging.
    Lung Cancer. 2021;155:156-162.
    PubMed     Abstract available


  294. LV W, Wang Y, Zhou C, Yuan M, et al
    Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study.
    Lung Cancer. 2021;155:78-86.
    PubMed     Abstract available


  295. ZHAO D, Hou F, Li M, Qi Y, et al
    A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma.
    Lung Cancer. 2021;155:193-195.
    PubMed    


  296. MORENO-RUIZ P, Corvigno S, Te Grootenhuis NC, La Fleur L, et al
    Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
    Lung Cancer. 2021;155:10-19.
    PubMed     Abstract available


  297. FOREST F, Casteillo F, Da Cruz V, Yvorel V, et al
    Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
    Lung Cancer. 2021;155:1-9.
    PubMed     Abstract available


  298. ARRIETA O, Salas AA, Cardona AF, Diaz-Garcia D, et al
    Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.
    Lung Cancer. 2021;155:183-190.
    PubMed     Abstract available


    April 2021
  299. DEBIEUVRE D, Juergens RA, Asselain B, Audigier-Valette C, et al
    Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Lung Cancer. 2021 Apr 30. pii: S0169-5002(21)00165.
    PubMed     Abstract available


  300. CHEN N, Li Q, Wang S, Xiong M, et al
    Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).
    Lung Cancer. 2021;156:82-90.
    PubMed     Abstract available


  301. NEWMAN NB, Osmundson EC
    Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.
    Lung Cancer. 2021 Apr 26. pii: S0169-5002(21)00161.
    PubMed     Abstract available


  302. FROESCH P, Mark M, Rothschild SI, Li Q, et al
    Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
    Lung Cancer. 2021;156:91-99.
    PubMed     Abstract available


  303. PALL G, Gautschi O
    Advances in the treatment of RET-fusion-positive lung cancer.
    Lung Cancer. 2021 Apr 24. pii: S0169-5002(21)00159.
    PubMed     Abstract available


  304. KUZDZAL J, Trybalski L, Hauer L, Cmiel A, et al
    Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study.
    Lung Cancer. 2021 Apr 22. pii: S0169-5002(21)00160.
    PubMed     Abstract available


  305. TAMMEMAGI MC, Darling GE, Schmidt H, Llovet D, et al
    Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Lung Cancer. 2021;156:31-40.
    PubMed     Abstract available


  306. ZHANG CC, Hou RP, Xia WY, Zeng WQ, et al
    Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study.
    Lung Cancer. 2021;156:100-108.
    PubMed     Abstract available


  307. HORIUCHI K, Sato T, Kuno T, Takagi H, et al
    Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021;156:59-67.
    PubMed     Abstract available


  308. BOGART JA, Wang X, Masters GA, Gao J, et al
    Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
    Lung Cancer. 2021;156:68-71.
    PubMed     Abstract available


  309. HSU CL, Tsai TH, Huang CK, Yang CY, et al
    Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
    Lung Cancer. 2021;156:50-58.
    PubMed     Abstract available


  310. VON DER THUSEN JH, Dumoulin DW, Maat APWM, Wolf J, et al
    ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype.
    Lung Cancer. 2021;156:72-75.
    PubMed     Abstract available


  311. MILLER HA, Yin X, Smith SA, Hu X, et al
    Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
    Lung Cancer. 2021;156:20-30.
    PubMed     Abstract available


  312. ITO S, Asahina H, Honjo O, Tanaka H, et al
    Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
    Lung Cancer. 2021;156:12-19.
    PubMed     Abstract available


  313. WATERHOUSE D, Lam J, Betts KA, Yin L, et al
    Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Lung Cancer. 2021;156:41-49.
    PubMed     Abstract available


  314. SCHREUDER A, Mets OM, Schaefer-Prokop CM, Jacobs C, et al
    Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
    Lung Cancer. 2021;156:5-11.
    PubMed     Abstract available


  315. VISSER MPJ, van Grimbergen I, Holters J, Barendregt WB, et al
    Performance insights of endobronchial ultrasonography (EBUS) and mediastinoscopy for mediastinal lymph node staging in lung cancer.
    Lung Cancer. 2021 Apr 7. pii: S0169-5002(21)00132.
    PubMed     Abstract available


  316. YANG L, Zhao W, Zhu H, Li X, et al
    PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;154:219-220.
    PubMed    


  317. COSTA FA, Amano MT, Asprino PF, Pavlick DC, et al
    Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.
    Lung Cancer. 2021;154:146-150.
    PubMed     Abstract available


  318. VOLCKMAR AL, Christopoulos P, Kirchner M, Allgauer M, et al
    Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
    Lung Cancer. 2021;154:131-141.
    PubMed     Abstract available


  319. XIONG A, Li C, Xu J, Yang X, et al
    Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
    Lung Cancer. 2021;154:124-130.
    PubMed     Abstract available


  320. SHANG X, Li Z, Sun J, Zhao C, et al
    Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Lung Cancer. 2021;154:105-112.
    PubMed     Abstract available


  321. WANG YL, Wu ZZ, Zhang HR, Chen DS, et al
    Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Lung Cancer. 2021;154:216-218.
    PubMed    


  322. ZHANG C, Wang H
    Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors.
    Lung Cancer. 2021;154:221-223.
    PubMed    


  323. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Lung Cancer. 2021;154:92-98.
    PubMed     Abstract available


  324. ZHANG C, Wang H
    The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores.
    Lung Cancer. 2021;154:214-215.
    PubMed    


  325. WEISSFERDT A, Pataer A, Swisher SG, Heymach JV, et al
    Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
    Lung Cancer. 2021;154:76-83.
    PubMed     Abstract available


  326. LI Z, Li F, Pan C, He Z, et al
    Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma.
    Lung Cancer. 2021;154:69-75.
    PubMed     Abstract available


  327. COLLAUD S, Alnajdawi Y, Stork T, Plones T, et al
    Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience.
    Lung Cancer. 2021;154:23-28.
    PubMed     Abstract available


  328. KATZ SI, Roshkovan L, Berger I, Friedberg JS, et al
    Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Lung Cancer. 2021;154:5-12.
    PubMed     Abstract available


  329. PATHIPATI MP, Yohannan TK, Tian L, Hornbacker K, et al
    Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.
    Lung Cancer. 2021;154:186-194.
    PubMed     Abstract available


    March 2021
  330. BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
    Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
    Lung Cancer. 2021;155:136-143.
    PubMed     Abstract available


  331. FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
    Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
    Lung Cancer. 2021;155:144-150.
    PubMed     Abstract available


  332. EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
    Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
    Lung Cancer. 2021;155:114-119.
    PubMed     Abstract available


  333. TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
    Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2021;155:120-126.
    PubMed     Abstract available


  334. EVERS J, de Jaeger K, Hendriks LEL, van der Sangen M, et al
    Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;155:103-113.
    PubMed     Abstract available


  335. TAO J, Jatoi A, Crawford J, Lam WWT, et al
    Role of dietary carbohydrates on risk of lung cancer.
    Lung Cancer. 2021;155:87-93.
    PubMed     Abstract available


  336. YUN JK, Lee GD, Choi S, Kim HR, et al
    The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis.
    Lung Cancer. 2021;155:94-102.
    PubMed     Abstract available


  337. PARK K, Chang GC, Curigliano G, Lim WT, et al
    Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Lung Cancer. 2021;155:127-135.
    PubMed     Abstract available


  338. AREDO JV, Purington N, Su L, Luo SJ, et al
    Metabolomic profiling for second primary lung cancer: A pilot case-control study.
    Lung Cancer. 2021;155:61-67.
    PubMed     Abstract available


  339. DAMHUS CS, Quentin JG, Malmqvist J, Siersma V, et al
    Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A longitudinal survey.
    Lung Cancer. 2021;155:46-52.
    PubMed     Abstract available


  340. YOH K, Seto T, Satouchi M, Nishio M, et al
    Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
    Lung Cancer. 2021;155:40-45.
    PubMed     Abstract available


  341. LIU J, Itchins M, Nagrial A, Cooper WA, et al
    Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2021;155:28-33.
    PubMed     Abstract available


  342. WANG W, Xu C, Chen H, Jia J, et al
    Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Lung Cancer. 2021;155:20-27.
    PubMed     Abstract available


  343. GARCIA CAMPELO MR, Lin HM, Zhu Y, Perol M, et al
    Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+non-small cell lung cancer (ALTA-1L).
    Lung Cancer. 2021;155:68-77.
    PubMed     Abstract available


  344. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Corrigendum to "Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods" [Lung Cancer 113 (2017) 1-3].
    Lung Cancer. 2021 Mar 4. pii: S0169-5002(21)00084.
    PubMed    


  345. MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
    Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Lung Cancer. 2021;155:151-155.
    PubMed     Abstract available


  346. ATTILI I, Tarantino P, Passaro A, Stati V, et al
    Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Lung Cancer. 2021;154:151-160.
    PubMed     Abstract available


  347. MORAES FY, Mansouri A, Dasgupta A, Ramotar M, et al
    Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
    Lung Cancer. 2021;155:34-39.
    PubMed     Abstract available


  348. KUNIMASA K
    A reply to "Cardiac dysfunction due to Osimertinib".
    Lung Cancer. 2021;153:195.
    PubMed    


  349. BOMMART S, Pujol JL, Coffy A, Daures JP, et al
    Authors reply to letter to the editor by Dr Degens et al.
    Lung Cancer. 2021;153:185.
    PubMed    


  350. ANAND K
    Cardiac dysfunction due to Osimertinib.
    Lung Cancer. 2021;153:193-194.
    PubMed    


  351. BABA K, Yoshida T, Shiotsuka M, Kobayashi O, et al
    Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.
    Lung Cancer. 2021;153:182-183.
    PubMed    


  352. ARAUJO-FILHO JAB, Chang J, Mayoral M, Plodkowski AJ, et al
    Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
    Lung Cancer. 2021;153:158-164.
    PubMed     Abstract available


  353. FUCHS V, Roisman L, Kian W, Daniel L, et al
    The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
    Lung Cancer. 2021;153:126-133.
    PubMed     Abstract available


  354. LI R, Jiang L, Zhou X, Lu Y, et al
    Pseudo-small cell transformation in EGFR-mutant adenocarcinoma.
    Lung Cancer. 2021;153:120-125.
    PubMed     Abstract available


  355. MASRORI P, Vaesen Bentein H, Raskin J, Montagna M, et al
    Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
    Lung Cancer. 2021;153:117-119.
    PubMed     Abstract available


  356. ZHAI X, Wu Q, Zeng Z, Suo J, et al
    OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:171-173.
    PubMed    


  357. WANG B, Chen R, Wang C, Chen H, et al
    PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:176-178.
    PubMed    


  358. REN P, Luo N, Qi Y, Wu Y, et al
    A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
    Lung Cancer. 2021;153:179-181.
    PubMed    


  359. DEVEAUX AE, Allen TA, Al Abo M, Qin X, et al
    RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
    Lung Cancer. 2021;153:90-98.
    PubMed     Abstract available


  360. LIU Y, Gao GF, Minna JD, Williams NS, et al
    Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.
    Lung Cancer. 2021;153:73-80.
    PubMed     Abstract available


  361. ZHOU F, Huang Y, Cai W, Li J, et al
    The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Lung Cancer. 2021;153:66-72.
    PubMed     Abstract available


  362. AMEMIYA R, Miyoshi T, Aokage K, Suzuki J, et al
    Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Lung Cancer. 2021;153:56-65.
    PubMed     Abstract available


  363. CHIA PL, Parakh S, Russell P, Gan HK, et al
    Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
    Lung Cancer. 2021;153:35-41.
    PubMed     Abstract available


  364. SUZUKI J, Aokage K, Neri S, Sakai T, et al
    Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
    Lung Cancer. 2021;153:1-10.
    PubMed     Abstract available


  365. KUNIMASA K, Oka T, Hara S, Yamada N, et al
    Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
    Lung Cancer. 2021;153:186-192.
    PubMed     Abstract available


    February 2021
  366. LIU L, Bai H, Seery S, Li S, et al
    Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis.
    Lung Cancer. 2021;158:74-84.
    PubMed     Abstract available


  367. LIU G, Brenner H, Chen C, Christiani D, et al
    A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?"
    Lung Cancer. 2021 Feb 26. pii: S0169-5002(21)00079.
    PubMed    


  368. WONG SK, Alex D, Bosdet I, Hughesman C, et al
    MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Lung Cancer. 2021;154:142-145.
    PubMed     Abstract available


  369. CHENG Y, Mok TS, Zhou X, Lu S, et al
    Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Lung Cancer. 2021;154:176-185.
    PubMed     Abstract available


  370. FOURDRAIN A, Epailly J, Blanchard C, Georges O, et al
    Lymphatic drainage of lung cancer follows an intersegmental pathway within the visceral pleura.
    Lung Cancer. 2021;154:118-123.
    PubMed     Abstract available


  371. KOK PS, Lee K, Lord S, Yang JC, et al
    Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
    Lung Cancer. 2021;154:113-117.
    PubMed     Abstract available


  372. KERR KM, Bibeau F, Thunnissen E, Botling J, et al
    The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Lung Cancer. 2021;154:161-175.
    PubMed     Abstract available


  373. MAO K, Liu F, Liu X, Khuri FR, et al
    Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
    Lung Cancer. 2021 Feb 19. pii: S0169-5002(21)00073.
    PubMed    


  374. GARON EB, Aerts J, Kim JS, Muehlenbein CE, et al
    Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
    Lung Cancer. 2021;155:53-60.
    PubMed     Abstract available


  375. OHARA S, Suda K, Fujino T, Hamada A, et al
    Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.
    Lung Cancer. 2021;154:84-91.
    PubMed     Abstract available


  376. LIU F, Liu Y, Liu X, Mao K, et al
    Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
    Lung Cancer. 2021 Feb 18. pii: S0169-5002(21)00072.
    PubMed    


  377. CHENG H, Zou Y, Shah CD, Fan N, et al
    First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2021;154:99-104.
    PubMed     Abstract available


  378. AHMED Z, Kennedy K, Subramanian J
    The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis.
    Lung Cancer. 2021;154:62-68.
    PubMed     Abstract available


  379. CHEN X, Muhammad KG, Madeeha C, Fu W, et al
    Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection.
    Lung Cancer. 2021 Feb 14. pii: S0169-5002(21)00065.
    PubMed     Abstract available


  380. SEBASTIAN M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, et al
    KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2021;154:51-61.
    PubMed     Abstract available


  381. HENG WS, Pore M, Meijer C, Hiltermann TJN, et al
    A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.
    Lung Cancer. 2021;154:13-22.
    PubMed     Abstract available


  382. SPAGGIARI L, Bertolaccini L, Facciolo F, Gallina FT, et al
    A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
    Lung Cancer. 2021;154:29-35.
    PubMed     Abstract available


  383. LAMOTE K, Van den Heuvel MM
    Where the nose is going to help the eye: Sniffing lung cancer.
    Lung Cancer. 2021 Feb 10. pii: S0169-5002(21)00063.
    PubMed    


  384. PALLARI E, Eriksson M, Billhult A, Billhult T, et al
    Lung cancer research and its citation on clinical practice guidelines.
    Lung Cancer. 2021;154:44-50.
    PubMed     Abstract available


  385. WANG S, Chen H, Zhong J, Qin H, et al
    Corrigendum to "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung" [Lung Cancer 135 (2019) 116-122].
    Lung Cancer. 2021 Feb 2. pii: S0169-5002(21)00014.
    PubMed    


  386. CAI C, Tang Y, Li Y, Chen Y, et al
    Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Lung Cancer. 2021;152:104-108.
    PubMed     Abstract available


  387. LI X, Liu J, Guo M, Cai H, et al
    NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
    Lung Cancer. 2021;152:202-204.
    PubMed    


  388. LAZAREV S, Rosenzweig K, Samstein R, Salgado LR, et al
    Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.
    Lung Cancer. 2021;152:157-164.
    PubMed     Abstract available


  389. ZHAO G, Chen L, Xiao M, Yang S, et al
    Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Lung Cancer. 2021;152:189-192.
    PubMed    


  390. MARCUSE F, Hochstenbag M, Hoeijmakers JGJ, Hamid MA, et al
    Subclinical myasthenia gravis in thymomas.
    Lung Cancer. 2021;152:143-148.
    PubMed     Abstract available


  391. HIROSE T, Ikegami M, Endo M, Matsumoto Y, et al
    Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Lung Cancer. 2021;152:135-142.
    PubMed     Abstract available


  392. LIANG P, Qi L, Guo T, You X, et al
    A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Lung Cancer. 2021;152:193-195.
    PubMed    


  393. MA H, Zhang Q, Duan Q, Zhang Q, et al
    Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
    Lung Cancer. 2021;152:196-198.
    PubMed    


  394. BLAKE-CERDA M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, et al
    Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Lung Cancer. 2021;152:119-126.
    PubMed     Abstract available


  395. GENDARME S, Matton L, Antoine M, Kerrou K, et al
    Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
    Lung Cancer. 2021;152:94-97.
    PubMed     Abstract available


  396. BERGER I, Simpson S, Friedberg JS, Culligan MJ, et al
    CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.
    Lung Cancer. 2021;152:34-38.
    PubMed     Abstract available


  397. CHAE M, Jeon JH, Chung JH, Lee SY, et al
    Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection.
    Lung Cancer. 2021;152:21-26.
    PubMed     Abstract available


  398. KWOK WC, Cheong TF, Chiang KY, Ho JCM, et al
    Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid.
    Lung Cancer. 2021;152:15-20.
    PubMed     Abstract available


  399. GHIRARDELLI P, Franceschini D, D'Aveni A, Dominici L, et al
    Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
    Lung Cancer. 2021;152:1-6.
    PubMed     Abstract available


    January 2021
  400. HEUVELMANS MA, van Ooijen PMA, Ather S, Silva CF, et al
    Lung cancer prediction by Deep Learning to identify benign lung nodules.
    Lung Cancer. 2021;154:1-4.
    PubMed     Abstract available


  401. ZOU Y, Wang Y, Jiang Z, Zhou Y, et al
    Breath profile as composite biomarkers for lung cancer diagnosis.
    Lung Cancer. 2021 Jan 30. pii: S0169-5002(21)00038.
    PubMed     Abstract available


  402. GOMES F, Faivre-Finn C, Mistry H, Bezjak A, et al
    Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
    Lung Cancer. 2021;153:165-170.
    PubMed     Abstract available


  403. FRIEDES C, Chakrabarti T, Olson S, Prichett L, et al
    Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
    Lung Cancer. 2021;154:36-43.
    PubMed     Abstract available


  404. EICHHORN F, Klotz LV, Kriegsmann M, Bischoff H, et al
    Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
    Lung Cancer. 2021;153:150-157.
    PubMed     Abstract available


  405. CHU X, Zhao J, Zhou J, Zhou F, et al
    Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020
    Lung Cancer. 2021 Jan 15. pii: S0169-5002(21)00015.
    PubMed    


  406. HASHEMI S, Fransen MF, Niemeijer A, Ben Taleb N, et al
    Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
    Lung Cancer. 2021;153:81-89.
    PubMed     Abstract available


  407. ZHOU J, Yu X, Hou L, Zhao J, et al
    Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
    Lung Cancer. 2021;153:143-149.
    PubMed     Abstract available


  408. TAKAGI H, Zhao S, Muto S, Yokouchi H, et al
    Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using (125)I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
    Lung Cancer. 2021;153:134-142.
    PubMed     Abstract available


  409. CHEN D, Kang P, Tao S, Li Q, et al
    Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer.
    Lung Cancer. 2021;153:99-107.
    PubMed     Abstract available


  410. OHTAKI Y, Shimizu K, Suzuki H, Suzuki K, et al
    Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
    Lung Cancer. 2021;153:108-116.
    PubMed     Abstract available


  411. IKEDA T, Kadota K, Yoshida C, Ishikawa R, et al
    The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a High risk of recurrence after resection of lung carcinoma.
    Lung Cancer. 2021;153:49-55.
    PubMed     Abstract available


  412. PROVENCIO M, Majem M, Guirado M, Massuti B, et al
    Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of su
    Lung Cancer. 2021;153:25-34.
    PubMed     Abstract available


  413. SANDFELD-PAULSEN B, Aggerholm-Pedersen N, Winther-Larsen A
    Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study.
    Lung Cancer. 2021;153:42-48.
    PubMed     Abstract available


  414. LI Z, Lin Y, Chi X, Xu M, et al
    Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.
    Lung Cancer. 2021 Jan 8. pii: S0169-5002(21)00007.
    PubMed    


  415. BRACKEN-CLARKE D, Kapoor D, Baird AM, Buchanan PJ, et al
    Vaping and lung cancer - A review of current data and recommendations.
    Lung Cancer. 2021;153:11-20.
    PubMed     Abstract available


  416. YANG ZY, Liu ZY, Mu CY, Jiang JH, et al
    Letter: Exploring the accuracy of biopsy in diagnosis of pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:97.
    PubMed    


  417. LI X, Zhang D, Li B, Zou B, et al
    Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Lung Cancer. 2021;151:39-43.
    PubMed     Abstract available


  418. FAIVRE-FINN C, Spigel DR, Senan S, Langer C, et al
    Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
    Lung Cancer. 2021;151:30-38.
    PubMed     Abstract available


  419. LI M, Tang Q, Chen S, Wang Y, et al
    A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Lung Cancer. 2021;151:98-100.
    PubMed    


  420. BUIKHUISEN WA, Steinbusch LC, Kodach LL, Tesselaar MET, et al
    Risk of second primary malignancies among patients with carcinoid of the lung.
    Lung Cancer. 2021;151:5-7.
    PubMed     Abstract available


  421. XIONG L, Li X, Chen D, Li S, et al
    GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:104-105.
    PubMed    


  422. TAKAHASHI T, Umeguchi H, Tateishi A, Yoshida T, et al
    Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
    Lung Cancer. 2021;151:1-4.
    PubMed     Abstract available


  423. BLONS H, Oudart JB, Merlio JP, Debieuvre D, et al
    PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
    Lung Cancer. 2021;151:69-75.
    PubMed     Abstract available


  424. WANG H, Shan Q, Guo J, Han X, et al
    PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Lung Cancer. 2021;151:76-83.
    PubMed     Abstract available


    December 2020
  425. DURHAM DD, Croswell JM, Marcus PM
    Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
    Lung Cancer. 2020;153:21-24.
    PubMed     Abstract available


  426. ABBAR B, De Castelbajac V, Gougis P, Assoun S, et al
    Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:109-118.
    PubMed     Abstract available


  427. LOBEFARO R, Viscardi G, Di Liello R, Massa G, et al
    Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
    Lung Cancer. 2020;152:165-173.
    PubMed     Abstract available


  428. RONDEN MI, Bahce I, Hashemi SMS, Dickhoff C, et al
    Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
    Lung Cancer. 2020;152:149-156.
    PubMed     Abstract available


  429. BRAILLON A
    Lung cancer outcomes: Are BMI and race clinically relevant?
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30749.
    PubMed    


  430. SHIBATA Y, Matsumoto S, Yoh K, Goto K, et al
    Evaluation of variant frequency in SARS-CoV-2 infection-related genes utilizing lung cancer genomic database.
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30733.
    PubMed    


  431. CASIRAGHI M, Sedda G, Del Signore E, Piperno G, et al
    Surgery for small cell lung cancer: When and how.
    Lung Cancer. 2020;152:71-77.
    PubMed     Abstract available


  432. MATSUURA Y, Ichinose J, Nakao M, Ninomiya H, et al
    Outcomes of nodal upstaging comparing video-assisted thoracoscopic surgery versus open thoracotomy for lung cancer.
    Lung Cancer. 2020;152:78-85.
    PubMed     Abstract available


  433. DE MARINIS F, Laktionov KK, Poltoratskiy A, Egorova I, et al
    Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    Lung Cancer. 2020;152:127-134.
    PubMed     Abstract available


  434. THOMAS PA, Couderc AL, Boulate D, Greillier L, et al
    Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?
    Lung Cancer. 2020;152:86-93.
    PubMed     Abstract available


  435. PENG W, Pu X, Jiang M, Wang J, et al
    Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Lung Cancer. 2020;152:66-70.
    PubMed     Abstract available


  436. YANG X, Man J, Chen H, Zhang T, et al
    Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis.
    Lung Cancer. 2020;152:49-57.
    PubMed     Abstract available


  437. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:27-33.
    PubMed     Abstract available


  438. JIANG M, Fares AF, Shepshelovich D, Yang P, et al
    The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.
    Lung Cancer. 2020;152:58-65.
    PubMed     Abstract available


  439. YANG GJ, Li J, Xu HY, Sun Y, et al
    Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Lung Cancer. 2020;152:39-48.
    PubMed     Abstract available


  440. VIGARIOS E, Rabeau A, Mazieres J, Sibaud V, et al
    Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management.
    Lung Cancer. 2020 Dec 4. pii: S0169-5002(20)30714.
    PubMed    


  441. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
    Lung Cancer. 2020 Dec 2. pii: S0169-5002(20)30691.
    PubMed    


  442. MI J, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:259-260.
    PubMed    


  443. LIU L, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:254-255.
    PubMed    


  444. LI X, Wang R, Wang L
    MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:256-258.
    PubMed    


  445. LI X, Wang L, Yu J
    ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:252-253.
    PubMed    


    November 2020
  446. ELFVING H, Brostrom E, Moens LNJ, Almlof J, et al
    Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Lung Cancer. 2020;151:53-59.
    PubMed     Abstract available


  447. MCCANN B, Muhr R, O'Rourke N, Milroy R, et al
    ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care.
    Lung Cancer. 2020;151:44-52.
    PubMed     Abstract available


  448. LU S, Wang J, Cheng Y, Mok T, et al
    Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
    Lung Cancer. 2020;152:7-14.
    PubMed     Abstract available


  449. GARON EB, Kim JS, Govindan R
    Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
    Lung Cancer. 2020;151:25-29.
    PubMed     Abstract available


  450. YAMAMOTO N, Seto T, Nishio M, Goto K, et al
    Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
    Lung Cancer. 2020;151:20-24.
    PubMed     Abstract available


  451. ARAKAWA S, Yoshida T, Shirasawa M, Takayanagi D, et al
    RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.
    Lung Cancer. 2020 Nov 20. pii: S0169-5002(20)30690.
    PubMed    


  452. LEE Y, Joo J, Lee YJ, Lee EK, et al
    Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2020;151:8-15.
    PubMed     Abstract available


  453. SONI S, Rastogi A, Prasad KT, Behera D, et al
    Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
    Lung Cancer. 2020;151:16-19.
    PubMed     Abstract available


  454. TSITSIAS T, Okiror L, Veres L, King J, et al
    New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery.
    Lung Cancer. 2020 Nov 16. pii: S0169-5002(20)30680.
    PubMed     Abstract available


  455. WAKUDA K, Yabe M, Kodama H, Nishioka N, et al
    Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
    Lung Cancer. 2020 Nov 15. pii: S0169-5002(20)30684.
    PubMed     Abstract available


  456. WANG M, Zhang D, Wang G, Xia J, et al
    HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
    Lung Cancer. 2020 Nov 13. pii: S0169-5002(20)30679.
    PubMed    


  457. JOOSTEN PJM, Dickhoff C, van der Noort V, Klomp HM, et al
    Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
    Lung Cancer. 2020;150:209-215.
    PubMed     Abstract available


  458. ZHOU Y, Wang B, Qu J, Yu F, et al
    Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2020;150:178-185.
    PubMed     Abstract available


  459. VICKERS AJ, Frese K, Galvin M, Carter M, et al
    Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
    Lung Cancer. 2020;150:216-220.
    PubMed     Abstract available


  460. GASSA A, Fassunke J, Schueten S, Kuhlmann L, et al
    Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
    Lung Cancer. 2020 Nov 5. pii: S0169-5002(20)30670.
    PubMed     Abstract available


  461. WU YL, Shi Y, Tan DSW, Xiaoqing L, et al
    Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Lung Cancer. 2020;150:240-246.
    PubMed     Abstract available


  462. LI JJN, Karim K, Sung M, Le LW, et al
    Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
    Lung Cancer. 2020;150:159-163.
    PubMed     Abstract available


  463. BISHNOI R, Shah C, Blaes A, Bian J, et al
    Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
    Lung Cancer. 2020;150:172-177.
    PubMed     Abstract available


  464. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2020 Nov 2. pii: S0169-5002(20)30663.
    PubMed     Abstract available


    October 2020
  465. YUN JK, Park I, Kim HR, Choi YS, et al
    Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.
    Lung Cancer. 2020;150:201-208.
    PubMed     Abstract available


  466. BERSANELLI M, Buti S, Giannarelli D, Leonetti A, et al
    Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
    Lung Cancer. 2020;150:123-131.
    PubMed     Abstract available


  467. FAEHLING M, Schumann C, Christopoulos P, Hoffknecht P, et al
    Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Lung Cancer. 2020;150:114-122.
    PubMed     Abstract available


  468. ZENG C, Gao Y, Xiong J, Lu J, et al
    Tumor-infiltrating CD8(+) T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
    Lung Cancer. 2020;150:139-144.
    PubMed     Abstract available


  469. YOTSUKURA M, Asamura H, Suzuki S, Asakura K, et al
    Corrigendum to "Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma" [Lung Cancer 145 (2020) 158-166].
    Lung Cancer. 2020 Oct 13. pii: S0169-5002(20)30639.
    PubMed    


  470. SUBBIAH V, Paz-Ares L, Besse B, Moreno V, et al
    Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
    Lung Cancer. 2020;150:90-96.
    PubMed     Abstract available


  471. WANG L, Ruan M, Lei B, Yan H, et al
    The potential of (18)F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.
    Lung Cancer. 2020;150:44-52.
    PubMed     Abstract available


  472. ZENG J, Mao WM, Chen QX, Luo TB, et al
    Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
    Lung Cancer. 2020;150:164-171.
    PubMed     Abstract available


  473. GARCIA-CAMPELO R, Arrieta O, Massuti B, Rodriguez-Abreu D, et al
    Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
    Lung Cancer. 2020;150:62-69.
    PubMed     Abstract available


  474. INAGAKI Y, Tamiya A
    Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'.
    Lung Cancer. 2020;148:179-180.
    PubMed    


    September 2020
  475. SHAO D, Cheng Y, Yuan ZS, Jiang BY, et al
    Value of interim (18)F-FDG PET/CT for predicting progression-free survival in stage B/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
    Lung Cancer. 2020;149:137-143.
    PubMed     Abstract available


  476. TAO H, Shi L, Zhou A, Li H, et al
    Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2020;149:154-161.
    PubMed     Abstract available


  477. ZHANG L, Yip R, Jirapatnakul A, Li M, et al
    Lung cancer screening intervals based on cancer risk.
    Lung Cancer. 2020;149:113-119.
    PubMed     Abstract available


  478. TAKEDA-MIYATA N, Konishi E, Tanaka T, Shimomura M, et al
    Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer.
    Lung Cancer. 2020;149:61-67.
    PubMed     Abstract available


  479. FUKUMOTO K, Mori S, Shintani Y, Okami J, et al
    Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study.
    Lung Cancer. 2020;149:120-129.
    PubMed     Abstract available


  480. GOLDMAN JW, Garassino MC, Chen Y, Ozguroglu M, et al
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Lung Cancer. 2020;149:46-52.
    PubMed     Abstract available


  481. REISSIG TM, Sara L, Ting S, Reis H, et al
    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
    Lung Cancer. 2020;149:10-16.
    PubMed     Abstract available


  482. LIU X, Hong L, Nilsson M, Hubert SM, et al
    Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2020;149:33-40.
    PubMed     Abstract available


  483. LI J, Wang Y, Zhang B, Xu J, et al
    Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Lung Cancer. 2020;149:17-22.
    PubMed     Abstract available


  484. ALBORELLI I, Bratic Hench I, Chijioke O, Prince SS, et al
    Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
    Lung Cancer. 2020;149:84-89.
    PubMed     Abstract available


  485. VOONG KR, Naidoo J
    Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.
    Lung Cancer. 2020 Sep 5. pii: S0169-5002(20)30596.
    PubMed    


  486. BERGHMANS T, Lievens Y, Aapro M, Baird AM, et al
    European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.
    Lung Cancer. 2020;150:221-239.
    PubMed     Abstract available


    August 2020
  487. BAUM P, Diers J, Haag J, Klotz L, et al
    Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany.
    Lung Cancer. 2020;149:78-83.
    PubMed     Abstract available


  488. CHU X, Zhao J, Zhou J, Zhou F, et al
    Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Lung Cancer. 2020;150:76-82.
    PubMed     Abstract available


  489. CHRISTOPOULOS P, Kirchner M, Roeper J, Saalfeld F, et al
    Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing.
    Lung Cancer. 2020;148:105-112.
    PubMed     Abstract available


  490. SUDA K, Murakami I, Obata K, Sakai K, et al
    Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
    Lung Cancer. 2020;148:100-104.
    PubMed     Abstract available


  491. ISMAIL RK, Schramel FMNH, van Dartel M, Hilarius DL, et al
    The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients.
    Lung Cancer. 2020;149:68-77.
    PubMed     Abstract available


  492. ANG L, Chan CPY, Yau WP, Seow WJ, et al
    Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis.
    Lung Cancer. 2020;148:129-137.
    PubMed     Abstract available


  493. YAMAMOTO M, Serizawa T, Sato Y, Higuchi Y, et al
    Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65-74 years.
    Lung Cancer. 2020;149:103-112.
    PubMed     Abstract available


  494. VAN VEGGEL B, de Langen AJ
    A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".
    Lung Cancer. 2020 Aug 8. pii: S0169-5002(20)30555.
    PubMed    


  495. RECK M, Syrigos K, Miliauskas S, Zochbauer-Muller S, et al
    Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Lung Cancer. 2020;148:159-165.
    PubMed     Abstract available


  496. WADDLE MR, Ko SJ, May J, Kaleem T, et al
    Improving identification of candidates for lung cancer screening in a high risk population.
    Lung Cancer. 2020;148:79-85.
    PubMed     Abstract available


  497. MADISON R, Schrock AB, Castellanos E, Gregg JP, et al
    Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Lung Cancer. 2020;148:69-78.
    PubMed     Abstract available


  498. SURYAVANSHI M, Jaipuria J, Panigrahi MK, Goyal N, et al
    CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.
    Lung Cancer. 2020;148:33-39.
    PubMed     Abstract available


  499. MARCHIONI A, Andrisani D, Tonelli R, Piro R, et al
    Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE).
    Lung Cancer. 2020;148:40-47.
    PubMed     Abstract available


  500. CHANG HL, Wei PJ, Wu KL, Huang HL, et al
    Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
    Lung Cancer. 2020;146:376-377.
    PubMed    


  501. WANG K, Liu Y, Hu T, Liu Y, et al
    The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
    Lung Cancer. 2020;146:373-375.
    PubMed    


    July 2020
  502. BARTLETT EC, Kemp SV, Ridge CA, Desai SR, et al
    Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
    Lung Cancer. 2020;148:12-19.
    PubMed     Abstract available


  503. ROJO F, Corassa M, Mavroudis D, Oz AB, et al
    International real-world study of DLL3 expression in patients with small cell lung cancer.
    Lung Cancer. 2020;147:237-243.
    PubMed     Abstract available


  504. YOUNG K, Jiang H, Marquez M, Yeung J, et al
    Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;147:214-220.
    PubMed     Abstract available


  505. VAD-NIELSEN J, Meldgaard P, Sorensen BS, Nielsen AL, et al
    Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.
    Lung Cancer. 2020;147:244-251.
    PubMed     Abstract available


  506. YANG G, Xu H, Yang L, Xu F, et al
    Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Lung Cancer. 2020;147:229-236.
    PubMed     Abstract available


  507. ZHENG J, Cao H, Li Y, Rao C, et al
    Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Lung Cancer. 2020;147:130-136.
    PubMed     Abstract available


  508. FAN Y, Chen J, Zhou C, Wang H, et al
    Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
    Lung Cancer. 2020;147:209-213.
    PubMed     Abstract available


  509. VARLOTTO JM, Voland R, DeCamp MM, Rava P, et al
    The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer.
    Lung Cancer. 2020;147:115-122.
    PubMed     Abstract available


  510. BEN DORI S, Aizic A, Sabo E, Hershkovitz D, et al
    Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Lung Cancer. 2020;147:91-98.
    PubMed     Abstract available


  511. SVEDBERG A, Bjorn N, Sigurgeirsson B, Pradhananga S, et al
    Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
    Lung Cancer. 2020;147:106-114.
    PubMed     Abstract available


  512. TOUMAZIS I, Bastani M, Han SS, Plevritis SK, et al
    Risk-Based lung cancer screening: A systematic review.
    Lung Cancer. 2020;147:154-186.
    PubMed     Abstract available


  513. JIA XH, Xu H, Geng LY, Jiao M, et al
    Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2020;147:143-153.
    PubMed     Abstract available


  514. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Corrigendum to "Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer" [Lung Cancer 142 (2020) 28-33].
    Lung Cancer. 2020 Jul 8. pii: S0169-5002(20)30485.
    PubMed    


  515. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery.
    Lung Cancer. 2020;147:71-76.
    PubMed     Abstract available


  516. HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
    A reply to "A modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing".
    Lung Cancer. 2020 Jul 3. pii: S0169-5002(20)30515.
    PubMed    


  517. REMON J, Nadal E, Domine M, Ruffinelli J, et al
    Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
    Lung Cancer. 2020;147:83-90.
    PubMed     Abstract available


  518. WANG Q, Li X, Ren S, Su C, et al
    HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Lung Cancer. 2020;147:99-105.
    PubMed     Abstract available


  519. DI NOIA V, D'Aveni A, Squadroni M, Beretta GD, et al
    Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
    Lung Cancer. 2020;145:208-210.
    PubMed    


  520. CHEN H, Louie AV
    High risk, same reward?
    Lung Cancer. 2020;145:221.
    PubMed    


  521. BALDINI E, Tibaldi C
    A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
    Lung Cancer. 2020;145:226.
    PubMed    


  522. INDINI A, Rijavec E, Grossi F
    Immune related adverse events and response to immunotherapy: Focus on corticosteroids.
    Lung Cancer. 2020;145:225.
    PubMed    


    June 2020
  523. CORSINI EM, Wang Q, Tran HT, Mitchell KG, et al
    Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.
    Lung Cancer. 2020;146:303-309.
    PubMed     Abstract available


  524. CUI W, Franchini F, Alexander M, Officer A, et al
    Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Lung Cancer. 2020;146:310-317.
    PubMed     Abstract available


  525. SUNG JH, Brown MC, Perez-Cosio A, Pratt L, et al
    Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study.
    Lung Cancer. 2020;147:1-11.
    PubMed     Abstract available


  526. GACHECHILADZE M, Skarda J, Skanderova D, Uberall I, et al
    Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Lung Cancer. 2020;147:30-38.
    PubMed     Abstract available


  527. CHEN C, Wang W, Yu Z, Tian S, et al
    Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.
    Lung Cancer. 2020;146:290-296.
    PubMed     Abstract available


  528. SOMMER MS, Vibe-Petersen J, Staerkind MB, Langer SW, et al
    Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial.
    Lung Cancer. 2020;146:285-289.
    PubMed     Abstract available


  529. LU S, Chen G, Sun Y, Sun S, et al
    A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lung Cancer. 2020;146:252-262.
    PubMed     Abstract available


  530. HURKMANS DP, Tamminga M, van Es B, Peters T, et al
    Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.
    Lung Cancer. 2020;146:341-349.
    PubMed     Abstract available


  531. CHEN LN, Spivack J, Cao T, Saqi A, et al
    Characteristics and outcomes of lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;146:297-302.
    PubMed     Abstract available


  532. WANG Z, Zhao J, Ma Z, Cui J, et al
    A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Lung Cancer. 2020;147:259-268.
    PubMed     Abstract available


  533. KOBAYASHI K, Soejima K, Fukunaga K, Shintani Y, et al
    Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
    Lung Cancer. 2020;146:236-243.
    PubMed     Abstract available


  534. WANG W, Cheng G, Zhang G, Song Z, et al
    Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
    Lung Cancer. 2020;146:224-229.
    PubMed     Abstract available


  535. GAGNE A, Orain M, Ionescu D, Tsao MS, et al
    Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Lung Cancer. 2020;146:276-284.
    PubMed     Abstract available


  536. NICOSIA L, Di Muzio J, Agolli L, Alongi F, et al
    What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?
    Lung Cancer. 2020;146:263-275.
    PubMed     Abstract available


  537. HUANG M, Insinga RP, Burke T, Zhang Y, et al
    In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
    Lung Cancer. 2020 Jun 17. pii: S0169-5002(20)30489.
    PubMed    


  538. LEI Y, Feng H, Qiang H, Shang Z, et al
    Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.
    Lung Cancer. 2020;146:244-251.
    PubMed     Abstract available


  539. LU M, Hu C, Wu F, Shu L, et al
    MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
    Lung Cancer. 2020;147:193-197.
    PubMed     Abstract available


  540. STAHEL RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, et al
    Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug.
    Lung Cancer. 2020;146:217-223.
    PubMed     Abstract available


  541. IGAWA S, Naoki K, Shintani Y, Sekine I, et al
    Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
    Lung Cancer. 2020;146:160-164.
    PubMed     Abstract available


  542. MENG P, Koopman B, Kok K, Ter Elst A, et al
    Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Lung Cancer. 2020 Jun 4. pii: S0169-5002(20)30472.
    PubMed     Abstract available


  543. FORNACON-WOOD I, Faivre-Finn C, O'Connor JPB, Price GJ, et al
    Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.
    Lung Cancer. 2020;146:197-208.
    PubMed     Abstract available


  544. CHEN D, Chen C, Chen Y
    Letter to the editor concerning 'Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer'.
    Lung Cancer. 2020;144:92.
    PubMed    


    May 2020
  545. JUNG HA, Sun JM, Lee SH, Ahn JS, et al
    Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Lung Cancer. 2020;146:112-119.
    PubMed     Abstract available


  546. JUNG HA, Noh JM, Sun JM, Lee SH, et al
    Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2020;146:23-29.
    PubMed     Abstract available


  547. ITO M, Kanda S, Yoshida T, Okuma Y, et al
    Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
    Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
    PubMed     Abstract available


  548. ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
    Covid-19 and lung cancer: A greater fatality rate?
    Lung Cancer. 2020;146:19-22.
    PubMed     Abstract available


  549. YANG YM, Jang Y, Lee SH, Kang B, et al
    AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Lung Cancer. 2020;146:70-77.
    PubMed     Abstract available


  550. ZHENG J, Zhu Y, Sun K, Shen Q, et al
    Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Lung Cancer. 2020;146:209-216.
    PubMed     Abstract available


  551. HAN J, Tian K, Yang J, Gong Y, et al
    Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Lung Cancer. 2020;146:42-49.
    PubMed     Abstract available


  552. RECK M, Luft A, Bondarenko I, Shevnia S, et al
    A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
    Lung Cancer. 2020;146:12-18.
    PubMed     Abstract available


  553. LIAO Z, Rivin Del Campo E, Salem A, Pang Q, et al
    Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.
    Lung Cancer. 2020;146:230-235.
    PubMed     Abstract available


  554. TESSEMA M, Tassew DD, Yingling CM, Do K, et al
    Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients.
    Lung Cancer. 2020;146:189-196.
    PubMed     Abstract available


  555. IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
    NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Lung Cancer. 2020;146:97-104.
    PubMed     Abstract available


  556. LEAL JL, Peters G, Szaumkessel M, Leong T, et al
    NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Lung Cancer. 2020;146:154-159.
    PubMed     Abstract available


  557. ZHAO D, Mambetsariev I, Li H, Chen C, et al
    Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
    Lung Cancer. 2020;146:174-181.
    PubMed     Abstract available


  558. LAM ACL, Aggarwal R, Cheung S, Stewart EL, et al
    Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis.
    Lung Cancer. 2020;146:134-144.
    PubMed     Abstract available


  559. SHI R, Filho SNM, Li M, Fares A, et al
    BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Lung Cancer. 2020;146:78-85.
    PubMed     Abstract available


  560. SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
    Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Lung Cancer. 2020;146:36-41.
    PubMed     Abstract available


  561. CHAN GH, Gwee YX, Low JL, Huang Y, et al
    Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
    Lung Cancer. 2020;146:145-153.
    PubMed     Abstract available


  562. MCFARLAND DC
    A comment on "Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms".
    Lung Cancer. 2020 May 20. pii: S0169-5002(20)30429.
    PubMed    


  563. ZENKE Y, Niho S, Umemura S, Ishihara M, et al
    Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged >/=75 years with squamous-cell lung cancer: TORG1322.
    Lung Cancer. 2020;146:182-188.
    PubMed     Abstract available


  564. CRENGLE S
    Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233-240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004.
    Lung Cancer. 2020 May 16. pii: S0169-5002(20)30377.
    PubMed    


  565. YUN JK, Lee GD, Choi S, Kim HR, et al
    Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Lung Cancer. 2020;146:105-111.
    PubMed     Abstract available


  566. ROSSI G, Caruso D, Nosseir S, Banchelli I, et al
    A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing.
    Lung Cancer. 2020 May 14. pii: S0169-5002(20)30430.
    PubMed    


  567. SUN F, Franks K, Murray L, Lilley J, et al
    Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?
    Lung Cancer. 2020;146:1-5.
    PubMed     Abstract available


  568. MORGENSZTERN D, Johnson M, Rudin CM, Rossi M, et al
    SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
    Lung Cancer. 2020;145:126-131.
    PubMed     Abstract available


  569. ISAKA T, Ito H, Nakayama H, Yokose T, et al
    Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
    Lung Cancer. 2020;145:111-118.
    PubMed     Abstract available


  570. BEAGAN JJ, Bach S, van Boerdonk RA, van Dijk E, et al
    Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Lung Cancer. 2020;145:173-180.
    PubMed     Abstract available


  571. QUIST M, Langer SW, Lillelund C, Winther L, et al
    Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial.
    Lung Cancer. 2020;145:76-82.
    PubMed     Abstract available


  572. DALL'OLIO FG, Maggio I, Massucci M, Mollica V, et al
    ECOG performance status >/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Lung Cancer. 2020;145:95-104.
    PubMed     Abstract available


  573. ROSSI D
    Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.
    Lung Cancer. 2020;145:83-84.
    PubMed     Abstract available


  574. DREVET G, Duruisseaux M, Lafitte C, Derberne M, et al
    A reply to "A comment on "Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience".
    Lung Cancer. 2020 May 6. pii: S0169-5002(20)30406.
    PubMed    


  575. HOFMAN V, Benzaquen J, Heeke S, Lassalle S, et al
    Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
    Lung Cancer. 2020;145:58-62.
    PubMed     Abstract available


  576. CHEN V, Iwama E, Kim IK, Giaccone G, et al
    Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
    Lung Cancer. 2020;145:48-57.
    PubMed     Abstract available


  577. TAKADA K, Takamori S, Yoneshima Y, Tanaka K, et al
    Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Lung Cancer. 2020;145:18-26.
    PubMed     Abstract available


  578. SERENO M, Gutierrez-Gutierrez G, Sandoval C, Falagan S, et al
    A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
    Lung Cancer. 2020 May 4. pii: S0169-5002(20)30399.
    PubMed    


  579. HANDRA-LUCA A
    C-Myc in mucinous colloid carcinoma of the lung.
    Lung Cancer. 2020;143:93-94.
    PubMed    


  580. SMUK G, Pajor G, Szuhai K, Morreau H, et al
    Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Lung Cancer. 2020;143:80-85.
    PubMed     Abstract available


  581. OKUNO T, Arakawa S, Yoshida T, Ohe Y, et al
    Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Lung Cancer. 2020;143:95-96.
    PubMed    


  582. KNEUERTZ PJ, Carbone DP, D'Souza DM, Shilo K, et al
    Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Lung Cancer. 2020;143:60-66.
    PubMed     Abstract available


  583. ZHOU Y, Jiang W, Zeng L, Mi J, et al
    A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Lung Cancer. 2020;143:55-59.
    PubMed     Abstract available


  584. SHERMAN S, Rotem O, Shochat T, Zer A, et al
    Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Lung Cancer. 2020;143:40-46.
    PubMed     Abstract available


  585. TREJO BITTAR HE, Jerome JA, Hartman D, Pantanowitz L, et al
    Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
    Lung Cancer. 2020;143:12-18.
    PubMed     Abstract available


    April 2020
  586. LIN YT, Tsai TH, Wu SG, Liu YN, et al
    Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lung Cancer. 2020;145:1-9.
    PubMed     Abstract available


  587. THOMAS R, Chen YH, Hatabu H, Mak RH, et al
    Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.
    Lung Cancer. 2020;145:132-139.
    PubMed     Abstract available


  588. DENG J, Zhao M, Wang T, She Y, et al
    A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
    Lung Cancer. 2020;145:33-39.
    PubMed     Abstract available


  589. SOLOMON BJ, Kim EE, Winter M, Monti K, et al
    Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2020;145:167-172.
    PubMed     Abstract available


  590. SCHEFFLER M, Holzem A, Kron A, Nogova L, et al
    Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
    Lung Cancer. 2020;144:40-48.
    PubMed     Abstract available


  591. LIU B, Henschke CI, Flores RM, Taioli E, et al
    Serum cotinine verification of self-reported smoking status among adults eligible for lung cancer screening in the 1999-2018 National Health and Nutrition Examination Survey.
    Lung Cancer. 2020;144:49-56.
    PubMed     Abstract available


  592. POPAT S, Grohe C, Corral J, Reck M, et al
    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Lung Cancer. 2020;144:76-84.
    PubMed     Abstract available


  593. DE RUITER JC, Heineman DJ, Daniels JM, van Diessen JN, et al
    The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
    Lung Cancer. 2020;144:64-70.
    PubMed     Abstract available


  594. BREADNER D, Blanchette P, Shanmuganathan S, Boldt RG, et al
    Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2020;144:57-63.
    PubMed     Abstract available


  595. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2020 Apr 18. pii: S0169-5002(20)30337.
    PubMed     Abstract available


  596. GOFFIN JR
    Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2020 Apr 4. pii: S0169-5002(20)30351.
    PubMed    


  597. ESCOIN-PEREZ C, Blasco S, Juan-Vidal O
    Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
    Lung Cancer. 2020;144:1-9.
    PubMed     Abstract available


  598. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Reply to the letter-to-the editor "Hospital volume and the case for centralisation of surgical services".
    Lung Cancer. 2020;142:140-141.
    PubMed    


  599. STIRLING R, Stenger M, Zalcberg J
    Comment on: 'Hospital lung surgery volume and patient outcomes'.
    Lung Cancer. 2020;142:138-139.
    PubMed    


  600. MOODLEY S, Lian EY, Crupi MJF, Hyndman BD, et al
    RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.
    Lung Cancer. 2020;142:123-131.
    PubMed     Abstract available


  601. SALA L, Mancin M, Pastore A, Seminati D, et al
    Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
    Lung Cancer. 2020;142:120-122.
    PubMed     Abstract available


  602. CHEN HF, Wang WX, Xu CW, Huang LC, et al
    A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Lung Cancer. 2020;142:59-62.
    PubMed     Abstract available


  603. ZUCALI PA, Perrino M, De Vincenzo F, Giordano L, et al
    A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Lung Cancer. 2020;142:132-137.
    PubMed     Abstract available


  604. CHAN OSH, Lam KC, Li JYC, Choi FPT, et al
    ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
    Lung Cancer. 2020;142:41-46.
    PubMed     Abstract available


  605. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer(1).
    Lung Cancer. 2020;142:28-33.
    PubMed     Abstract available


  606. AN N, Leng X, Wang X, Sun Y, et al
    Survival comparison of Three histological subtypes of lung squamous cell carcinoma: A population-based propensity score matching analysis.
    Lung Cancer. 2020;142:13-19.
    PubMed     Abstract available


    March 2020
  607. FRUH M, Panje CM, Reck M, Blackhall F, et al
    Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
    Lung Cancer. 2020;146:6-11.
    PubMed     Abstract available


  608. VERONESI G, Navone N, Novellis P, Dieci E, et al
    Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Lung Cancer. 2020;143:73-79.
    PubMed     Abstract available


  609. BOYSEN FYNBOE EBERT E, McCulloch T, Holmskov Hansen K, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Lung Cancer. 2020;143:67-72.
    PubMed     Abstract available


  610. MA L, Zhang Q, Dong Y, Li H, et al
    SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30347.
    PubMed    


  611. YANG G, Li J, Xu H, Yang Y, et al
    EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30344.
    PubMed     Abstract available


  612. PETERS S, Shaw AT, Besse B, Felip E, et al
    Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
    Lung Cancer. 2020;144:10-19.
    PubMed     Abstract available


  613. SHEINSON D, Wong WB, Wu N, Mansfield AS, et al
    Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2020;143:86-92.
    PubMed     Abstract available


  614. ITO M, Miyata Y, Tsutani Y, Ito H, et al
    Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Lung Cancer. 2020;141:107-113.
    PubMed     Abstract available


  615. GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
    Cytology for PD-L1 testing: A systematic review.
    Lung Cancer. 2020;141:101-106.
    PubMed     Abstract available


  616. LI C, Shen Y, Hu F, Chu T, et al
    Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
    Lung Cancer. 2020;141:72-77.
    PubMed     Abstract available


  617. ZHAO J, Lin G, Zhuo M, Fan Z, et al
    Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
    Lung Cancer. 2020;141:114-118.
    PubMed     Abstract available


    February 2020
  618. PERTEJO-FERNANDEZ A, Ricciuti B, Hammond SP, Marty FM, et al
    Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
    Lung Cancer. 2020 Feb 24. pii: S0169-5002(20)30310.
    PubMed     Abstract available


  619. WANG F, Qin J, Xie F, Wu Q, et al
    Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Lung Cancer. 2020;140:118-120.
    PubMed    


  620. LAM WS, Creaney J, Chen FK, Chin WL, et al
    A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lung Cancer. 2020;140:87-92.
    PubMed     Abstract available


  621. WU H, Dong S, Li X, Shi L, et al
    Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Lung Cancer. 2020;140:80-86.
    PubMed     Abstract available


  622. REALE ML, Chiari R, Tiseo M, Vitiello F, et al
    Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Lung Cancer. 2020;140:71-79.
    PubMed     Abstract available


  623. BALDINI E, Lunghi A, Cortesi E, Turci D, et al
    Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Lung Cancer. 2020;140:59-64.
    PubMed     Abstract available


  624. GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
    Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Lung Cancer. 2020;140:42-45.
    PubMed     Abstract available


  625. SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
    Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Lung Cancer. 2020;140:35-41.
    PubMed     Abstract available


  626. EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
    Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Lung Cancer. 2020;140:116-117.
    PubMed    


  627. SHOJI S, Watanabe S, Takamura K, Umezu H, et al
    First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
    Lung Cancer. 2020;140:113-115.
    PubMed    


    January 2020
  628. ZHOU F, Zhao W, Chen X, Zhang J, et al
    Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF(V600E) mutation.
    Lung Cancer. 2020;139:219-220.
    PubMed    


  629. ZELTSMAN M, Dozier J, Vaghjiani RG, Poch A, et al
    Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity.
    Lung Cancer. 2020;139:68-72.
    PubMed     Abstract available


  630. PINSKY P, Gierada DS
    Long-term cancer risk associated with lung nodules observed on low-dose screening CT scans.
    Lung Cancer. 2020;139:179-184.
    PubMed     Abstract available


  631. MIYAKE N, Ochi N, Yamane H, Fukazawa T, et al
    Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
    Lung Cancer. 2020;139:170-178.
    PubMed     Abstract available


  632. WIESWEG M, Herold T, Metzenmacher M, Eberhardt WE, et al
    Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
    Lung Cancer. 2020;139:165-168.
    PubMed     Abstract available


  633. YANG S, Mao S, Li X, Zhao C, et al
    Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Lung Cancer. 2020;139:133-139.
    PubMed     Abstract available


  634. STOCKHAMMER P, Ploenes T, Theegarten D, Schuler M, et al
    Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Lung Cancer. 2020;139:124-132.
    PubMed     Abstract available


  635. ZHANG JT, Li Y, Yan LX, Zhu ZF, et al
    Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Lung Cancer. 2020;139:118-123.
    PubMed     Abstract available


  636. WANG B, Tang Y, Chen Y, Hamal P, et al
    Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules.
    Lung Cancer. 2020;139:103-110.
    PubMed     Abstract available


  637. CHEN X, Pang Z, Wang Y, Bie F, et al
    The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database.
    Lung Cancer. 2020;139:94-102.
    PubMed     Abstract available


  638. SOUSA AC, Silveira C, Janeiro A, Malveiro S, et al
    Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
    Lung Cancer. 2020;139:35-40.
    PubMed     Abstract available


  639. CARACENI A, Lo Dico S, Zecca E, Brunelli C, et al
    Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
    Lung Cancer. 2020;139:13-17.
    PubMed     Abstract available


  640. RIBEIRO MFSA, Alessi JVM, Oliveira LJC, Gongora ABL, et al
    Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Lung Cancer. 2020;139:9-12.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: